<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006271.pub3" GROUP_ID="SYMPT" ID="875206011109145038" MERGED_FROM="" MODIFIED="2017-05-05 12:04:02 +0100" MODIFIED_BY="Anna Erskine" REVIEW_NO="143" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="9.0">
<COVER_SHEET MODIFIED="2017-05-04 16:15:26 +0100" MODIFIED_BY="Anna Erskine">
<TITLE MODIFIED="2014-08-11 15:59:42 +0100" MODIFIED_BY="[Empty name]">Haloperidol for the treatment of nausea and vomiting in palliative care patients</TITLE>
<CONTACT>
<PERSON ID="A48EBF6082E26AA2002589C3D5C23099" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Saskie</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Dorman</LAST_NAME>
<SUFFIX/>
<POSITION>Consultant in Palliative Medicine</POSITION>
<EMAIL_1>saskie.dorman@poole.nhs.uk</EMAIL_1>
<EMAIL_2>saskiedorman@hotmail.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Palliative Medicine</DEPARTMENT>
<ORGANISATION>Poole Hospital NHS Foundation Trust</ORGANISATION>
<ADDRESS_1>Longfleet Road</ADDRESS_1>
<ADDRESS_2/>
<CITY>Poole</CITY>
<ZIP>BH15 2JB</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 1202 448118</PHONE_1>
<PHONE_2>+44 1202 448115</PHONE_2>
<FAX_1>+44 1202 448119</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2017-05-04 16:14:56 +0100" MODIFIED_BY="Anna Erskine">
<PERSON ID="z1403121501580956036530626659864" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Fay</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Murray-Brown</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>faymurray-brown@nhs.net</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Speciality Training Programme in Palliative Medicine</DEPARTMENT>
<ORGANISATION>Peninsula Deanery</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Devon</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="A48EBF6082E26AA2002589C3D5C23099" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Saskie</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Dorman</LAST_NAME>
<SUFFIX/>
<POSITION>Consultant in Palliative Medicine</POSITION>
<EMAIL_1>saskie.dorman@poole.nhs.uk</EMAIL_1>
<EMAIL_2>saskiedorman@hotmail.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Palliative Medicine</DEPARTMENT>
<ORGANISATION>Poole Hospital NHS Foundation Trust</ORGANISATION>
<ADDRESS_1>Longfleet Road</ADDRESS_1>
<ADDRESS_2/>
<CITY>Poole</CITY>
<ZIP>BH15 2JB</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 1202 448118</PHONE_1>
<PHONE_2>+44 1202 448115</PHONE_2>
<FAX_1>+44 1202 448119</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2017-05-04 16:14:55 +0100" MODIFIED_BY="Anna Erskine">
<UP_TO_DATE>
<DATE DAY="1" MONTH="11" YEAR="2014"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="1" MONTH="11" YEAR="2014"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="11" YEAR="2017"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2006"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2009"/>
<LAST_CITATION_ISSUE ISSUE="11" YEAR="2015"/>
</DATES>
<WHATS_NEW MODIFIED="2017-05-04 16:15:26 +0100" MODIFIED_BY="Anna Erskine">
<WHATS_NEW_ENTRY EVENT="STABLE" MODIFIED="2017-05-04 16:15:26 +0100" MODIFIED_BY="Anna Erskine">
<DATE DAY="4" MONTH="5" YEAR="2017"/>
<DESCRIPTION>
<P>See <LINK TAG="PUBLIC_NOTES" TYPE="SECTION">Published notes</LINK>.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2017-05-04 16:15:12 +0100" MODIFIED_BY="Anna Erskine">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2017-05-04 16:15:10 +0100" MODIFIED_BY="Anna Erskine">
<DATE DAY="6" MONTH="3" YEAR="2015"/>
<DESCRIPTION>
<P>This review has been updated; a risk of bias table has been added and a PRISMA flowchart have been included for this update.</P>
<P>Two ongoing studies have been identified in trials registers.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2017-05-04 16:15:12 +0100" MODIFIED_BY="Anna Erskine">
<DATE DAY="15" MONTH="10" YEAR="2014"/>
<DESCRIPTION>
<P>One new study has been identified for inclusion, but the conclusions remain unchanged.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2015-03-25 15:10:38 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="8" MONTH="6" YEAR="2014"/>
<DESCRIPTION>
<P>Edited by authors</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2015-03-25 15:10:33 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="24" MONTH="3" YEAR="2014"/>
<DESCRIPTION>
<P>Change of author</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-03-25 15:10:36 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="24" MONTH="3" YEAR="2014"/>
<DESCRIPTION>
<P>Review updated</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2014-06-08 15:59:18 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="9" MONTH="11" YEAR="2009"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-10-30 12:04:48 +0000" MODIFIED_BY="Jessica Thomas">
<DATE DAY="30" MONTH="6" YEAR="2008"/>
<DESCRIPTION>
<P>Protocol converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2015-07-30 13:15:46 +0100" MODIFIED_BY="Anna Hobson">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2017-05-04 16:15:33 +0100" MODIFIED_BY="Anna Erskine">
<SUMMARY MODIFIED="2015-10-13 12:42:54 +0100" MODIFIED_BY="Anna Hobson">
<TITLE MODIFIED="2008-10-14 17:05:14 +0100" MODIFIED_BY="Jessica R Thomas">Haloperidol for the treatment of nausea and vomiting in palliative care patients</TITLE>
<SUMMARY_BODY MODIFIED="2015-10-13 12:42:54 +0100" MODIFIED_BY="Anna Hobson">
<P>Haloperidol is often used to help control nausea (feeling sick) or vomiting (being sick), both of which are common problems for patients with serious life-threatening illnesses. Haloperidol can be given by mouth or by injection. There has been some research looking at how this drug works in nausea and vomiting caused by surgery and when trying to prevent nausea and vomiting caused by anti-cancer treatments.</P>
<P>This is an update of the original review published in 2009 for which no studies met the inclusion criteria. For this update, in a search of the published literature in November 2014 we found one moderate quality randomised controlled trial which compared ABH (Ativan®, Benadryl®, Haldol®) gel, containing haloperidol and two other medications, to placebo.</P>
<P>The trial showed no difference between ABH gel and placebo. However it has previously been shown that haloperidol is not absorbed after applying ABH gel, so this result is not surprising. We identified a trial of haloperidol for nausea and vomiting in patients with cancer, with initial results presented at a conference. This suggests that haloperidol is effective in 65% of patients, but the results were not fully published at the time of our review. A further trial has opened in Australia, comparing haloperidol with another medication used for nausea, methotrimeprazine (levomepromazine).</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2015-10-03 12:36:55 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2015-08-23 12:49:50 +0100" MODIFIED_BY="Denise M Mitchell">
<P>Nausea and vomiting are common symptoms in patients with terminal, incurable illnesses. Both nausea and vomiting can be distressing. Haloperidol is commonly prescribed to relieve these symptoms. This is an updated version of the original Cochrane review published in Issue 2, 2009, of Haloperidol for the treatment of nausea and vomiting in palliative care patients.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2015-03-29 17:03:01 +0100" MODIFIED_BY="[Empty name]">
<P>To evaluate the efficacy and adverse events associated with the use of haloperidol for the treatment of nausea and vomiting in palliative care patients.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2015-10-03 12:16:46 +0100" MODIFIED_BY="[Empty name]">
<P>For this updated review, we performed updated searches of CENTRAL, EMBASE and MEDLINE in November 2013 and in November 2014. We searched controlled trials registers in March 2015 to identify any ongoing or unpublished trials. We imposed no language restrictions. For the original review, we performed database searching in August 2007, including CENTRAL, MEDLINE, EMBASE, CINAHL and AMED, using relevant search terms and synonyms. Handsearching complemented the electronic searches (using reference lists of included studies, relevant chapters and review articles) for the original review.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2015-07-06 14:08:12 +0100" MODIFIED_BY="[Empty name]">
<P>We considered randomised controlled trials (RCTs) of haloperidol for the treatment of nausea or vomiting, or both, in any setting, for inclusion. The studies had to be conducted with adults receiving palliative care or suffering from an incurable progressive medical condition. We excluded studies where nausea or vomiting, or both, were thought to be secondary to pregnancy or surgery.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2015-01-07 14:24:51 +0000" MODIFIED_BY="[Empty name]">
<P>We imported records from each of the electronic databases into a bibliographic package and merged them into a core database where we inspected titles, keywords and abstracts for relevance. If it was not possible to accept or reject an abstract with certainty, we obtained the full text of the article for further evaluation. The two review authors independently assessed studies in accordance with the inclusion criteria. There were no differences in opinion between the authors with regard to the assessment of studies.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2015-10-03 12:36:55 +0100" MODIFIED_BY="[Empty name]">
<P>We considered 27 studies from the 2007 search. In this update we considered a further 38 studies from the 2013 search, and two in the 2014 search. We identified one RCT of moderate quality with low risk of bias overall which met the inclusion criteria for this update, comparing ABH (Ativan®, Benadryl®, Haldol®) gel, applied to the wrist, with placebo for the relief of nausea in 22 participants. ABH gel includes haloperidol as well as diphenhydramine and lorazepam. The gel was not significantly better than placebo in this small study; however haloperidol is reported not to be absorbed significantly when applied topically, therefore the trial does not address the issue of whether haloperidol is effective or well-tolerated when administered by other routes (e.g. by mouth, subcutaneously or intravenously). We identified one ongoing trial of haloperidol for the management of nausea and vomiting in patients with cancer, with initial results published in a conference abstract suggesting that haloperidol is effective for 65% of patients. The trial had not been fully published at the time of our review. A further trial has opened, comparing oral haloperidol with oral methotrimeprazine (levomepromazine) for patients with cancer and nausea unrelated to their treatment, which we aim to include in the next review update.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2015-08-23 10:06:38 +0100" MODIFIED_BY="Denise M Mitchell">
<P>Since the last version of this review, we found one new study for inclusion but the conclusion remains unchanged. There is incomplete evidence from published RCTs to determine the effectiveness of haloperidol for nausea and vomiting in palliative care. Other than the trial of ABH gel vs placebo, we did not identify any fully published RCTs exploring the effectiveness of haloperidol for nausea and vomiting in palliative care patients for this update, but two trials are underway.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2015-10-13 12:20:01 +0100" MODIFIED_BY="Anna Hobson">
<BACKGROUND MODIFIED="2015-10-03 12:59:26 +0100" MODIFIED_BY="[Empty name]">
<P>This is an updated version of the original Cochrane review published in Issue 2, 2009, of Haloperidol for the treatment of nausea and vomiting in palliative care patients.</P>
<P>All patients with terminal illness should have access to palliative care, independent of their diagnosis, and we wanted to reflect this in our review. Defining this population has been identified as a problem in previous reviews. We used the same definition as <LINK REF="REF-Hirst-2001" TYPE="REFERENCE">Hirst 2001</LINK> to give some consistency with other Cochrane reviews: "adult patients in any setting, receiving palliative care or suffering an incurable progressive medical condition".</P>
<CONDITION MODIFIED="2015-10-03 12:59:26 +0100" MODIFIED_BY="[Empty name]">
<P>Nausea and vomiting are common symptoms for patients with terminal, incurable illnesses. Both symptoms can be distressing. Between 6% and 68% of patients with advanced cancer are troubled by nausea (<LINK REF="REF-Solano-2006" TYPE="REFERENCE">Solano 2006</LINK>), and nausea and vomiting are also common in other conditions, for example long-term lung conditions and heart failure (<LINK REF="REF-Edmonds-2001" TYPE="REFERENCE">Edmonds 2001</LINK>; <LINK REF="REF-Klinkenberg-2004" TYPE="REFERENCE">Klinkenberg 2004</LINK>; <LINK REF="REF-Solano-2006" TYPE="REFERENCE">Solano 2006</LINK>). There are many potential causes in patients with terminal illness, including biochemical abnormalities (for example, kidney failure, high calcium salts in the blood), drugs (for example, iron supplements or morphine), or the underlying illness (for example, cancer deposits in the liver or brain). Anxiety can also be associated with nausea. Medications used to improve nausea and vomiting are called antiemetics. Antiemetics can help control symptoms while actions are taken to try and treat the underlying cause (<LINK REF="REF-Twycross-1998" TYPE="REFERENCE">Twycross 1998</LINK>; <LINK REF="REF-Bentley-2001" TYPE="REFERENCE">Bentley 2001</LINK>; <LINK REF="REF-Mannix-2004" TYPE="REFERENCE">Mannix 2004</LINK>; <LINK REF="REF-Reuben-1986" TYPE="REFERENCE">Reuben 1986</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2015-08-23 16:43:10 +0100" MODIFIED_BY="Denise M Mitchell">
<P>Haloperidol is in the butyrophenone class of drugs and acts as an antagonist on dopamine receptors. Haloperidol is used alone or in combination with other antiemetics orally, subcutaneously, intravenously or intramuscularly and can also be used intranasally (<LINK REF="REF-Miller-2008" TYPE="REFERENCE">Miller 2008</LINK>). It is also available in a compound gel including lorazepam and diphenhydramine, although it is reported not to be absorbed by this route (<LINK REF="STD-Smith-2012a" TYPE="STUDY">Smith 2012a</LINK>).</P>
<P>Possible side effects of haloperidol include sedation, movement disturbance and arrhythmias (<LINK REF="REF-Twycross-2014" TYPE="REFERENCE">Twycross 2014</LINK>). Neuroleptic malignant syndrome is a more serious but less common adverse event. This has numerous features including fever, altered consciousness and muscle rigidity, and can be fatal (<LINK REF="REF-Susman-2001" TYPE="REFERENCE">Susman 2001</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2015-08-28 14:03:12 +0100" MODIFIED_BY="[Empty name]">
<P>Dopamine is an important neurotransmitter in the vomiting centre in the brain. Haloperidol acts as an antagonist at dopamine receptors in the brain (<LINK REF="REF-Smith-2012b" TYPE="REFERENCE">Smith 2012b</LINK>; <LINK REF="REF-Twycross-2014" TYPE="REFERENCE">Twycross 2014</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2015-08-28 14:03:27 +0100" MODIFIED_BY="[Empty name]">
<P>There is little evidence from published randomised trials for many of the drugs used for these symptoms in this patient group (for example, cyclizine, haloperidol or levomepromazine) (<LINK REF="STD-Glare-2004" TYPE="STUDY">Glare 2004</LINK>). Haloperidol is commonly used in this setting to treat nausea and vomiting (<LINK REF="REF-Critchley-2001" TYPE="REFERENCE">Critchley 2001</LINK>; <LINK REF="REF-Smith-2012b" TYPE="REFERENCE">Smith 2012b</LINK>; <LINK REF="REF-To-2014" TYPE="REFERENCE">To 2014</LINK>). A small uncontrolled study (42 participants with cancer and nausea or vomiting unrelated to cancer treatment) suggests some evidence for effectiveness in the setting: 61% of evaluable participants had partial or complete control of nausea at day two (47% of all participants) and 74% at day five (40% of all participants) (<LINK REF="STD-Hardy-2010" TYPE="STUDY">Hardy 2010</LINK>). We felt it important to update the previous systematic review to establish the current evidence base from randomised trials (<LINK REF="STD-Perkins-2009" TYPE="STUDY">Perkins 2009</LINK>).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2015-08-28 14:03:30 +0100" MODIFIED_BY="[Empty name]">
<P>To evaluate the efficacy and adverse events associated with the use of haloperidol for the treatment of nausea and vomiting in palliative care patients.</P>
</OBJECTIVES>
<METHODS MODIFIED="2015-10-03 12:17:23 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2015-08-28 14:03:38 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES>
<P>Randomised controlled trials (RCTs) of haloperidol for the treatment of nausea or vomiting, or both, in any setting.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2008-10-10 16:13:47 +0100" MODIFIED_BY="Jessica R Thomas">
<SUBSECTION>
<HEADING LEVEL="4">Inclusion criteria</HEADING>
<P>Adults receiving palliative care or suffering from an incurable progressive medical condition. Adults suffering from nausea or vomiting, or both.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Exclusion criteria</HEADING>
<P>Nausea or vomiting, or both, thought to be secondary to pregnancy or surgery.</P>
</SUBSECTION>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2015-08-28 14:03:33 +0100" MODIFIED_BY="[Empty name]">
<P>Studies where haloperidol was used as an antiemetic (alone or in addition to other agents) including any dose of haloperidol, via any route, over any duration of follow-up.</P>
<SUBSECTION>
<HEADING LEVEL="4">Acceptable comparators</HEADING>
<UL>
<LI>Placebo.</LI>
<LI>Other drug.</LI>
<LI>Non-pharmacological intervention.</LI>
</UL>
</SUBSECTION>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2015-08-28 14:03:38 +0100" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2015-08-28 14:03:34 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Patient-reported nausea severity.</LI>
<LI>Patient-reported vomiting severity.</LI>
</UL>
<P>As there is a wide variety of instruments to measure these symptoms, we accepted any measure.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2015-08-28 14:03:38 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Quality of life measurement.</LI>
<LI>Acceptability of treatment.</LI>
<LI>Need for rescue antiemetic medication.</LI>
<LI>Adverse events.</LI>
<LI>Withdrawal from study because of side effects.</LI>
</UL>
<P>Ideally, valid outcome measures would have been used but we would not have excluded studies on the basis of their outcome measures.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2015-10-03 12:17:23 +0100" MODIFIED_BY="[Empty name]">
<P>For the original review we searched the electronic databases including CENTRAL, MEDLINE (1950 to August 2007), EMBASE (1980 to August 2007), CINAHL (1981 to August 2007) and AMED (1985 to August 2007), using relevant search terms and synonyms. The basic search strategy was ("haloperidol" OR "butyrophenone") AND ("nausea" OR "vomiting"), modified for each database. For the original review, handsearching complemented the electronic searches (using reference lists of included studies, relevant chapters and review articles). We did not impose a language restriction on studies. See <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for the MEDLINE search strategy. We performed database searching in August 2007. For this update, we performed updated electronic searches of CENTRAL, MEDLINE and EMBASE in September 2012 and again in November 2013 and in November 2014.</P>
<P>We also searched clinical trials registers, the WHO International Clinical Trials Registry Platform (<A HREF="http://www.who.int/ictrp/en/">http://www.who.int/ictrp/en/</A>), <A HREF="http://clinicaltrials.gov/">ClinicalTrials.gov</A>, Current Controlled Trials (<A HREF="http://www.controlled-trials.com/">www.controlled-trials.com/</A>) and the EU Clinical Trials Register (<A HREF="http://clinicaltrialsregister.eu">clinicaltrialsregister.eu</A>) for this update on 06 March 2015, using the search term "haloperidol".</P>
<ELECTRONIC_SEARCHES MODIFIED="2015-10-03 12:14:57 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the following databases without language restrictions.</P>
<UL>
<LI>The Cochrane Central Register of Controlled Trials (CENTRAL) (via <I>The Cochrane Library</I>, 2007) for the previous version, and (Issue 10 of 12, 2014) for this update.</LI>
<LI>MEDLINE (via Ovid) 1946 to August 2007 for the previous version, and November 2014 for this update.</LI>
<LI>EMBASE (via Ovid) 1974 to August 2007 for the previous version, and November 2014 for this update.</LI>
<LI>CINAHL (via EBSCO) 1981 to August 2007 for the previous version.</LI>
<LI>AMED (via Ovid) 1985 to August 2007 for the previous version.</LI>
</UL>
<P>We used medical subject headings (MeSH) or equivalent and text word terms. There were no language or date restrictions. The search strategies for CENTRAL, MEDLINE, EMBASE, CINAHL and AMED are in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2015-08-28 14:04:33 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the metaRegister of controlled trials (mRCT) (<A HREF="http://www.controlled-trials.com/mrct">www.controlled-trials.com/mrct</A>), clinicaltrials.gov (<A HREF="http://www.clinicaltrials.gov/">www.clinicaltrials.gov</A>) and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<A HREF="http://apps.who.int/trialsearch/">http://apps.who.int/trialsearch/</A>) on 06 March 2015 to identify additional completed or ongoing studies.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2015-08-28 14:06:35 +0100" MODIFIED_BY="[Empty name]">
<P>For the original review, records were imported from each of the above electronic databases into the bibliographic package EndNote 9 and merged into a core database where titles, keywords and abstracts were inspected for relevance. If it was not possible to accept or reject an abstract with certainty, the full text of the article was obtained for further evaluation. We reviewed the updated searches from 2013 and 2014 in a Word document including title, keywords and abstracts.</P>
<STUDY_SELECTION MODIFIED="2015-05-31 19:02:07 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors independently assessed abstracts and possible studies for inclusion in accordance with the above inclusion criteria (PP and SD for the review published in 2009 (<LINK REF="STD-Perkins-2009" TYPE="STUDY">Perkins 2009</LINK>) and FM-B and SD for this updated review). There were no differences in opinion between review authors with regards to assessment of studies.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2015-08-28 14:06:12 +0100" MODIFIED_BY="[Empty name]">
<P>Data were entered into RevMan 5.3 (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>).</P>
<P>We planned to assess studies for treatment effect (see <LINK TAG="CRIT_OUTCOMES" TYPE="SECTION">Types of outcome measures</LINK> above), specifying numbers needed to treat for an additional beneficial outcome (NNTB) and numbers needed to treat for an additional harmful outcome (NNTH).</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2015-07-30 13:11:48 +0100" MODIFIED_BY="Anna Hobson">
<P>We graded studies that met the inclusion criteria in the Risk of bias table below (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>).</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2015-05-31 21:07:19 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment effect was given as the mean difference in the change in nausea scores from baseline (<LINK REF="STD-Fletcher-2014" TYPE="STUDY">Fletcher 2014</LINK>). Other estimations of treatment effect would also have been considered.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2015-05-31 20:07:13 +0100" MODIFIED_BY="[Empty name]">
<P>We accepted randomisation of the individual patient.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2015-05-31 19:57:30 +0100" MODIFIED_BY="[Empty name]">
<P>Had missing data been potentially relevant to the findings of the review, we would have contacted the authors to include the missing data if available; if unavailable, we would have used imputation (e.g. last outcome value carried forward).</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2015-08-28 14:06:14 +0100" MODIFIED_BY="[Empty name]">
<P>Palliative care populations can be diverse, including a range of diagnoses as well as demographic characteristics. We did not exclude studies on the basis of scales used, raising the possibility of several different outcome measures being used. If the heterogeneity of studies allowed we would have performed a meta-analysis. If the I<SUP>2 </SUP>statistic value was &gt; 50% we would have used a random-effects model (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2015-05-31 20:23:30 +0100" MODIFIED_BY="[Empty name]">
<P>We planned to assess heterogeneity using L&#8217;Abbé plots (<LINK REF="REF-L_x2019_Abb_x00e9_-1987" TYPE="REFERENCE">L&#8217;Abbé 1987</LINK>), a visual method for assessing differences in results of individual studies.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2015-08-28 14:06:25 +0100" MODIFIED_BY="[Empty name]">
<P>Quantiative meta-analysis would only be used if studies were sufficiently similar to do so on the basis of I<SUP>2</SUP> statistical test to assess heterogeneity (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). In the qualitative synthesis, risk of bias is noted.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2015-08-28 14:06:35 +0100" MODIFIED_BY="[Empty name]">
<P>If there had been sufficient data we had planned to perform subgroup analyses using the following subgroups identified a priori:</P>
<SUBSECTION>
<HEADING LEVEL="4">Population subgroups</HEADING>
<UL>
<LI>Diagnoses of patients.</LI>
<LI>Likely mechanism of nausea/vomiting.</LI>
<LI>Prognoses of patients.</LI>
<LI>Age of patients.</LI>
<LI>Gender of patients.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Intervention subgroups</HEADING>
<UL>
<LI>Route of administration.</LI>
<LI>Drug dose (&lt; 2 mg/24 hours; 2 mg to 5 mg/24 hours; &gt; 5 mg/24 hours),</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcome subgroups</HEADING>
<UL>
<LI>Nausea.</LI>
<LI>Vomiting.</LI>
</UL>
</SUBSECTION>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2015-06-25 07:47:05 +0100" MODIFIED_BY="[Empty name]">
<P>Sensitivity analysis was not undertaken as there were insufficient studies identified to warrant it.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2015-10-13 12:18:55 +0100" MODIFIED_BY="Anna Hobson">
<STUDY_DESCRIPTION MODIFIED="2015-10-03 12:01:44 +0100" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2015-10-03 12:01:44 +0100" MODIFIED_BY="[Empty name]">
<P>We obtained 27 full studies (one in German) as potentially fitting the inclusion criteria for the 2009 review; we obtained a further 38 studies in 2013 as potentially fitting the inclusion criteria. None of these studies met the criteria for inclusion (see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). A further two studies were obtained from the search in November 2014 including one randomised study (<LINK REF="STD-Fletcher-2014" TYPE="STUDY">Fletcher 2014</LINK>) and one published as a conference abstract (<LINK REF="STD-ACTRN12610000481077" TYPE="STUDY">ACTRN12610000481077</LINK>).</P>
<P>We also identified the two ongoing trials and one uncompleted trial below in trials registers, from 190 records (163 trials) in the WHO International Clinical Trials Registry Platform, 137 records in ClinicalTrials.gov, 18 records in Current Controlled Trials and 33 records in the EU Clinical Trials Register (date of searches 06 March 2015):</P>
<SUBSECTION>
<HEADING LEVEL="3">Trials in progress</HEADING>
<UL>
<LI>A two-stage trial of response to antiemetic therapy in patients with cancer and nausea not related to anticancer therapy. Study 1 is a randomised, open-label study of guideline-driven, targeted antiemetic therapy versus single-agent antiemetic therapy (<LINK REF="STD-ACTRN12610000481077" TYPE="STUDY">ACTRN12610000481077</LINK>). Haloperidol is the treatment in arm 2 of this study (escalated in a three-step schedule from 1 mg/24 hours to 3 mg/24hours orally or subcutaneously). It is also used in combination with dexamethasone for a subset of arm 1 (participants with mechanical bowel obstruction). Preliminary results have been published as a conference abstract (<LINK REF="STD-ACTRN12610000481077" TYPE="STUDY">ACTRN12610000481077</LINK>). The authors conclude that haloperidol is effective for 65% of patients, with no significant difference between haloperidol or targeted antiemetic therapy, however the full results were not published at the time of our review.</LI>
<LI>A study for participants with cancer who experience ongoing nausea, not related to their treatment, despite taking standard and usual medications, that studies the effectiveness of oral methotrimeprazine (levomepromazine) versus oral haloperidol. This study was registered 23 February 2015, with a target sample size of 126. Patients will be randomised to receive blinded encapsulated oral methotrimeprazine (6.25mg) or oral haloperidol (1.5mg) given once daily for three days, with a potential to increase to twice daily if there is no response at 24 hours or 48 hours. Responses will be assessed using a 0 to 10 numeric rating scale of nausea (<LINK REF="STD-ACTRN12615000177550" TYPE="STUDY">ACTRN12615000177550</LINK>).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Trial stopped early</HEADING>
<UL>
<LI>A study of olanzapine versus haloperidol for the relief of nausea and vomiting in patients with advanced cancer (registered 7 June 2005 but stopped early due to poor recruitment on 30 June 2008; <LINK REF="REF-Pereira-2012" TYPE="REFERENCE">Pereira 2012</LINK>).</LI>
</UL>
</SUBSECTION>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2015-08-28 14:10:33 +0100" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="STD-Fletcher-2014" TYPE="STUDY">Fletcher 2014</LINK> compared topical "ABH Gel" (Ativan® (lorazepam), Benadryl® (diphenhydramine) and Haldol® (haloperidol)) with placebo gel in 22 patients with nausea. Participants had cancer, or had a consultation with the palliative care team; patients receiving chemotherapy were excluded. The study sample size was reported to be large enough to detect a significant change in nausea (two points on a ten point scale), with a power of 80%. Patients were randomised to a sequence of treatments: one group that applied the ABH gel initially and then the placebo; the other group applied the placebo first followed by ABH gel. Twenty patients completed both treatments. It is unclear which arm was completed by the two participants who dropped out, ABH gel or placebo. The study is of moderate quality overall (GRADE criteria, <LINK REF="REF-Sch_x00fc_nemann-2011" TYPE="REFERENCE">Schünemann 2011</LINK>).</P>
<P>See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2015-05-31 20:56:39 +0100" MODIFIED_BY="[Empty name]">
<P>In total 27 studies were excluded in the initial review (<LINK REF="STD-Perkins-2009" TYPE="STUDY">Perkins 2009</LINK>) with a further 37 studies excluded in this update (<LINK TAG="EXCLUDED_STUDIES" TYPE="SECTION">Excluded studies</LINK>, with reasons shown below in <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2015-07-17 19:09:42 +0100" MODIFIED_BY="[Empty name]">
<P>The comparison of ABH gel with placebo (<LINK REF="STD-Fletcher-2014" TYPE="STUDY">Fletcher 2014</LINK>) recruited 22 participants of whom 20 completed the trial. The study sample size was calculated using a paired t-test to be adequate to show that placebo was not inferior to ABH gel (power 80%, common standard deviation 1.5 at a one-sided significance level of 5%). Risk of bias is summarised in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>.</P>
<ALLOCATION MODIFIED="2015-06-03 05:51:18 +0100" MODIFIED_BY="[Empty name]">
<P>In the study of ABH gel (<LINK REF="STD-Fletcher-2014" TYPE="STUDY">Fletcher 2014</LINK>), participants were allocated a sequence of treatments randomly, using a randomisation list generated by the study statistician.</P>
</ALLOCATION>
<BLINDING MODIFIED="2015-06-03 05:54:25 +0100" MODIFIED_BY="[Empty name]">
<P>The study of ABH gel (<LINK REF="STD-Fletcher-2014" TYPE="STUDY">Fletcher 2014</LINK>) is described as double-blind. Participants received ABH gel or placebo gel in randomised order. Participants and investigators were not aware of which treatment was being used.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2015-06-03 05:56:40 +0100" MODIFIED_BY="[Empty name]">
<P>Two of the 22 participants did not complete the study (<LINK REF="STD-Fletcher-2014" TYPE="STUDY">Fletcher 2014</LINK>). It is not clear which arm of the study they were in. This is unlikely to affect the overall results of the study.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2015-06-03 05:59:43 +0100" MODIFIED_BY="[Empty name]">
<P>Placebo is reported to be non-inferior to ABH gel (<LINK REF="STD-Fletcher-2014" TYPE="STUDY">Fletcher 2014</LINK>). Reporting bias appears unlikely in this instance.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2015-07-17 19:09:42 +0100" MODIFIED_BY="[Empty name]">
<P>There is some risk of recruitment bias in <LINK REF="STD-Fletcher-2014" TYPE="STUDY">Fletcher 2014</LINK>: all participants were reported to have an active cancer diagnosis, and some were recruited from a bone marrow transplant clinic. The study population may not therefore fully reflect the heterogeneity of patients seen by palliative care services. Also, some potential participants with more severe nausea may have chosen not to take part in the study because they preferred a subcutaneous or intravenous injection of medication for nausea, with a likely more rapid onset of action.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2015-10-13 12:18:55 +0100" MODIFIED_BY="Anna Hobson">
<P>Haloperidol in the form of ABH topical gel did not reduce nausea or vomiting any more than placebo.</P>
<P>The primary study outcome was nausea which was self-assessed using a 0&#8211;10 scale, with zero being no nausea and 10 being the worst possible nausea. The number of episodes of vomiting over time was recorded and participants completed the Memorial Symptom Assessment Scale-Condensed which was used to determine the secondary outcomes and side effects. Participants were also asked at the end of each treatment period, "Did you feel the treatment was effective?,&#8221; and &#8220;Did you have any side effects from the drug?&#8221; On completion of both arms of the study, participants were asked, &#8220;Which drug helped you more?,&#8221; &#8220;Which drug did you think was the real ABH gel?,&#8221; and &#8220;Which was the placebo?&#8221; (<LINK REF="STD-Fletcher-2014" TYPE="STUDY">Fletcher 2014</LINK>)</P>
<SUBSECTION>
<HEADING LEVEL="3">Primary review outcomes</HEADING>
<P>Patient-reported nausea: no significant difference was found between placebo and ABH gel rubbed into the wrists, with both treatments showing a small reduction in nausea scores at 60 minutes (1.7+/- 2.05 for ABH gel, 0.9 +/- 2.45 for placebo; not statistically significant P value = 0.42).</P>
<P>Patient-reported vomiting: observed episodes of vomiting were recorded rather than patient-reported. ABH gel did not reduce vomiting more than placebo (not statistically significant P value = 0.34), but most patients did not have episodes of vomiting in any case.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary review outcomes</HEADING>
<P>Quality of life: not measured (note short term study).</P>
<P>Acceptability of treatment: of the 21 participants answering the question, seven thought the ABH gel was effective and 14 thought it was not. One reported a side effect of drowsiness.</P>
<P>Need for rescue antiemetic medication: not reported.</P>
<P>Adverse events: of 21 participants answering the question "Did you have any side effects from the drug?", 20 said they had no side effects from the drug and one said they did (drowsiness). One participant did not answer the question.</P>
<P>Withdrawal from study because of side effects: none (two participants did not complete both arms of the study, said to be because they did not want to wait to complete the study; they denied side effects) (<LINK REF="STD-Fletcher-2014" TYPE="STUDY">Fletcher 2014</LINK>).</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2015-10-03 12:50:54 +0100" MODIFIED_BY="[Empty name]">
<P>This is an updated version of the original Cochrane review published in Issue 2, 2009, on Haloperidol for the treatment of nausea and vomiting in palliative care patients.</P>
<P>For this update, we identified one small RCT of moderate quality which compared ABH gel, containing haloperidol, diphenhydramine and lorazepam, with placebo (<LINK REF="STD-Fletcher-2014" TYPE="STUDY">Fletcher 2014</LINK>). However haloperidol is not absorbed significantly from application of ABH gel (<LINK REF="STD-Smith-2012a" TYPE="STUDY">Smith 2012a</LINK>) so this study does not add to the evidence base for the effectiveness of haloperidol as an antiemetic. Other than this (<LINK REF="STD-Fletcher-2014" TYPE="STUDY">Fletcher 2014</LINK>) there are no fully published randomised controlled trials of haloperidol for nausea or vomiting in a palliative care population, although it is frequently used by palliative care physicians (<LINK REF="REF-Prommer-2012" TYPE="REFERENCE">Prommer 2012</LINK>; <LINK REF="REF-Smith-2012b" TYPE="REFERENCE">Smith 2012b</LINK>; <LINK REF="REF-To-2014" TYPE="REFERENCE">To 2014</LINK>).</P>
<P>A previous systematic review of haloperidol in this context retrieved case reports and case series only (<LINK REF="REF-Critchley-2001" TYPE="REFERENCE">Critchley 2001</LINK>). In a systematic review of antiemetics in the treatment of nausea in far-advanced cancer only case series were found to support the use of haloperidol (<LINK REF="STD-Glare-2004" TYPE="STUDY">Glare 2004</LINK>). A review of the management of nausea and vomiting in people with cancer and other chronic diseases described haloperidol as "likely to be beneficial" based on consensus (<LINK REF="REF-Keeley-2007" TYPE="REFERENCE">Keeley 2007</LINK>). Indeed haloperidol is thought by some to be one of four essential drugs for the management of symptoms at the end of life (<LINK REF="REF-Lindqvist-2013" TYPE="REFERENCE">Lindqvist 2013</LINK>).</P>
<P>However, initial results from a trial comparing haloperidol with a targeted antiemetic approach suggests that either approach is effective for 65% of patients (<LINK REF="STD-ACTRN12610000481077" TYPE="STUDY">ACTRN12610000481077</LINK>); the full results were not published at the time of our review. This is similar to the findings from a previous uncontrolled study which suggested a response rate of 61% at day two (47% on intention to treat analysis (<LINK REF="STD-Hardy-2010" TYPE="STUDY">Hardy 2010</LINK>). It is encouraging that despite the difficulties encountered by some researchers trying to conduct RCTs of the effectiveness of haloperidol, two randomised studies are currently underway (<LINK REF="STD-ACTRN12610000481077" TYPE="STUDY">ACTRN12610000481077</LINK>; <LINK REF="STD-ACTRN12615000177550" TYPE="STUDY">ACTRN12615000177550</LINK>).</P>
<P>There are RCTs of haloperidol in post-operative nausea and vomiting (<LINK REF="REF-Barton-1975" TYPE="REFERENCE">Barton 1975</LINK>), gastrointestinal disorders (<LINK REF="STD-Christman-1974" TYPE="STUDY">Christman 1974</LINK>; <LINK REF="STD-Robbins-1975" TYPE="STUDY">Robbins 1975</LINK>), prophylaxis against nausea and vomiting associated with radiotherapy (<LINK REF="STD-Cole-1974" TYPE="STUDY">Cole 1974</LINK>) and chemotherapy (<LINK REF="STD-Neidhart-1981" TYPE="STUDY">Neidhart 1981</LINK>). A meta-analysis calculated that the number needed to treat for an additional beneficial outcome (NNTB) (with 2 mg) to prevent postoperative nausea or vomiting compared with placebo was four (<LINK REF="STD-Buttner-2004" TYPE="STUDY">Buttner 2004</LINK>). It is not clear to what extent these studies are applicable to palliative care populations, although they may help to inform practice (<LINK REF="REF-McLean-2013" TYPE="REFERENCE">McLean 2013</LINK>). The causes and mechanisms of nausea and vomiting may be somewhat different in palliative care. This may have an impact on the effectiveness of interventions.</P>
<SUMMARY_OF_RESULTS MODIFIED="2015-10-03 12:01:44 +0100" MODIFIED_BY="[Empty name]">
<P>For this update, we identified one RCT which compared ABH gel, containing haloperidol, diphenhydramine and lorazepam, with placebo (<LINK REF="STD-Fletcher-2014" TYPE="STUDY">Fletcher 2014</LINK>). However haloperidol is not absorbed significantly from topical application of ABH gel (<LINK REF="STD-Smith-2012a" TYPE="STUDY">Smith 2012a</LINK>) so this study does not add to the evidence base for the effectiveness of haloperidol as an antiemetic. Other than <LINK REF="STD-Fletcher-2014" TYPE="STUDY">Fletcher 2014</LINK> there are no fully published randomised controlled trials of haloperidol for nausea or vomiting in a palliative care population, although two randomised studies are currently underway (<LINK REF="STD-ACTRN12610000481077" TYPE="STUDY">ACTRN12610000481077</LINK>; <LINK REF="STD-ACTRN12615000177550" TYPE="STUDY">ACTRN12615000177550</LINK>).</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2015-08-28 14:14:08 +0100" MODIFIED_BY="[Empty name]">
<P>There is incomplete evidence from published RCTs to determine the effectiveness of haloperidol for nausea and vomiting in palliative care. The study of ABH gel (<LINK REF="STD-Fletcher-2014" TYPE="STUDY">Fletcher 2014</LINK>) does not refute the apparent anti-emetic effect of haloperidol in clinical practice and studies in other settings (<LINK REF="STD-Christman-1974" TYPE="STUDY">Christman 1974</LINK>; <LINK REF="STD-Cole-1974" TYPE="STUDY">Cole 1974</LINK>; <LINK REF="REF-Barton-1975" TYPE="REFERENCE">Barton 1975</LINK>; <LINK REF="STD-Robbins-1975" TYPE="STUDY">Robbins 1975</LINK>; <LINK REF="STD-Neidhart-1981" TYPE="STUDY">Neidhart 1981</LINK>; <LINK REF="STD-Buttner-2004" TYPE="STUDY">Buttner 2004</LINK>; <LINK REF="REF-McLean-2013" TYPE="REFERENCE">McLean 2013</LINK>) since haloperidol is not absorbed by this route (<LINK REF="STD-Smith-2012a" TYPE="STUDY">Smith 2012a</LINK>).</P>
<P>Haloperidol remains frequently prescribed as an antiemetic by palliative care physicians (<LINK REF="REF-Prommer-2012" TYPE="REFERENCE">Prommer 2012</LINK>; <LINK REF="REF-Smith-2012b" TYPE="REFERENCE">Smith 2012b</LINK>; <LINK REF="REF-To-2014" TYPE="REFERENCE">To 2014</LINK>).</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2015-08-28 14:14:23 +0100" MODIFIED_BY="[Empty name]">
<P>Only one published RCT of moderate quality has been identified in this updated review (<LINK REF="STD-Fletcher-2014" TYPE="STUDY">Fletcher 2014</LINK>). This is a small study of ABH gel (applied topically) compared with placebo. Since haloperidol is not absorbed via this route (<LINK REF="STD-Smith-2012a" TYPE="STUDY">Smith 2012a</LINK>), this study neither supports nor refutes the role of haloperidol as an antiemetic.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2015-06-03 06:23:39 +0100" MODIFIED_BY="[Empty name]">
<P>The review methods sought to minimise bias by conducting a thorough search of the published literature to identify relevant studies, using predefined criteria to select studies for inclusion, and independent review by two authors. The review authors sometimes prescribe haloperidol as an antiemetic in palliative care settings.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2015-10-03 12:50:54 +0100" MODIFIED_BY="[Empty name]">
<P>A previous systematic review of haloperidol in this context retrieved case reports and case series only (<LINK REF="REF-Critchley-2001" TYPE="REFERENCE">Critchley 2001</LINK>). In a systematic review of antiemetics in the treatment of nausea in far-advanced cancer only case series were found to support the use of haloperidol (<LINK REF="STD-Glare-2004" TYPE="STUDY">Glare 2004</LINK>). A review of the management of nausea and vomiting in people with cancer and other chronic diseases described haloperidol as "likely to be beneficial" based on consensus (<LINK REF="REF-Keeley-2007" TYPE="REFERENCE">Keeley 2007</LINK>). Indeed haloperidol is thought by some to be one of four essential drugs for the management of symptoms at the end of life (<LINK REF="REF-Lindqvist-2013" TYPE="REFERENCE">Lindqvist 2013</LINK>).</P>
<P>Although we did not systematically review the evidence in other contexts, we found RCTs of haloperidol in post-operative nausea and vomiting (<LINK REF="REF-Barton-1975" TYPE="REFERENCE">Barton 1975</LINK>), gastrointestinal disorders (<LINK REF="STD-Christman-1974" TYPE="STUDY">Christman 1974</LINK>; <LINK REF="STD-Robbins-1975" TYPE="STUDY">Robbins 1975</LINK>), prophylaxis against nausea and vomiting associated with radiotherapy (<LINK REF="STD-Cole-1974" TYPE="STUDY">Cole 1974</LINK>) and chemotherapy (<LINK REF="STD-Neidhart-1981" TYPE="STUDY">Neidhart 1981</LINK>). A meta-analysis calculated that the number needed to treat for a beneficial outcome (NNTB) (with 2 mg) to prevent postoperative nausea or vomiting compared with placebo was four (<LINK REF="STD-Buttner-2004" TYPE="STUDY">Buttner 2004</LINK>). It is not clear to what extent these studies are applicable to palliative care populations, although they may help to inform practice (<LINK REF="REF-McLean-2013" TYPE="REFERENCE">McLean 2013</LINK>). The causes and mechanisms of nausea and vomiting may be somewhat different in palliative care. This may have an impact on the effectiveness of interventions.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2015-10-13 12:20:01 +0100" MODIFIED_BY="Anna Hobson">
<IMPLICATIONS_PRACTICE MODIFIED="2015-10-13 12:20:01 +0100" MODIFIED_BY="Anna Hobson">
<P>Since the last version of this review, we found one new study for inclusion (<LINK REF="STD-Fletcher-2014" TYPE="STUDY">Fletcher 2014</LINK>) but the conclusions remain unchanged.</P>
<P>There is a lack of published evidence for the use of haloperidol for nausea and vomiting in palliative care. A study comparing ABH gel (containing haloperidol, diphenhydramine and lorazepam) to placebo showed no significant difference (<LINK REF="STD-Fletcher-2014" TYPE="STUDY">Fletcher 2014</LINK>). However haloperidol is not absorbed significantly following application of the gel (<LINK REF="STD-Smith-2012a" TYPE="STUDY">Smith 2012a</LINK>). No other RCTs of haloperidol in this setting have been fully published but two trials are underway (<LINK REF="STD-ACTRN12610000481077" TYPE="STUDY">ACTRN12610000481077</LINK>; <LINK REF="STD-ACTRN12615000177550" TYPE="STUDY">ACTRN12615000177550</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Implications for people with nausea or vomiting in the context of advanced disease</HEADING>
<P>Haloperidol is often used to help control nausea (feeling sick) or vomiting (being sick). The evidence to support this is largely from other settings - for example, haloperidol to control sickness after surgical operations, chemotherapy or radiotherapy. There are no published randomised trials of haloperidol to control nausea and vomiting in people with advanced disease, other than a small study of a gel containing haloperidol (ABH gel) compared with placebo. No significant difference was found between ABH gel and placebo, which is not surprising as haloperidol is not absorbed by this route. Two randomised studies are underway to compare haloperidol with other medications for nausea and vomiting.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Implications for clinicians</HEADING>
<P>Haloperidol may still be used as an antiemetic, though there is no evidence from RCTs in the palliative care context to quantify its effectiveness used orally or by injection. A small study of a gel containing haloperidol (ABH gel) compared with placebo found no significant difference (<LINK REF="STD-Fletcher-2014" TYPE="STUDY">Fletcher 2014</LINK>), which is not surprising as haloperidol is not absorbed by this route (<LINK REF="STD-Smith-2012a" TYPE="STUDY">Smith 2012a</LINK>). Initial results from a trial which is underway suggest that it may be effective in 65% of patients (<LINK REF="STD-ACTRN12610000481077" TYPE="STUDY">ACTRN12610000481077</LINK>). Further results from this <LINK REF="STD-ACTRN12610000481077" TYPE="STUDY">ACTRN12610000481077</LINK> and another ongoing study, <LINK REF="STD-ACTRN12615000177550" TYPE="STUDY">ACTRN12615000177550</LINK>, will help to inform practice which so far has been guided by clinical experience, consensus (<LINK REF="REF-Keeley-2007" TYPE="REFERENCE">Keeley 2007</LINK>), an uncontrolled study (<LINK REF="STD-Hardy-2010" TYPE="STUDY">Hardy 2010</LINK>) and research in other settings (<LINK REF="REF-McLean-2013" TYPE="REFERENCE">McLean 2013</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Implications for policy makers</HEADING>
<P>Haloperidol is frequently prescribed as an antiemetic (<LINK REF="REF-Prommer-2012" TYPE="REFERENCE">Prommer 2012</LINK>; <LINK REF="REF-Smith-2012b" TYPE="REFERENCE">Smith 2012b</LINK>; <LINK REF="REF-To-2014" TYPE="REFERENCE">To 2014</LINK>), although there is no evidence from RCTs in the palliative care context to quantify its effectiveness used orally or by injection. A small study of a topically applied gel containing haloperidol (ABH gel) compared with placebo found no significant difference (<LINK REF="STD-Fletcher-2014" TYPE="STUDY">Fletcher 2014</LINK>), which is not surprising as haloperidol is not absorbed by this route (<LINK REF="STD-Smith-2012a" TYPE="STUDY">Smith 2012a</LINK>). Initial results from a trial which is underway suggest that it may be effective in 65% of patients (<LINK REF="STD-ACTRN12610000481077" TYPE="STUDY">ACTRN12610000481077</LINK>). Further results from <LINK REF="STD-ACTRN12610000481077" TYPE="STUDY">ACTRN12610000481077</LINK> and another ongoing study, <LINK REF="STD-ACTRN12615000177550" TYPE="STUDY">ACTRN12615000177550</LINK>, will help to inform practice which so far has been guided by clinical experience, consensus (<LINK REF="REF-Keeley-2007" TYPE="REFERENCE">Keeley 2007</LINK>) and research in other settings (<LINK REF="REF-McLean-2013" TYPE="REFERENCE">McLean 2013</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Implications for funders</HEADING>
<P>There is limited evidence for the use of haloperidol as an antiemetic in palliative care although it is commonly prescribed. Current clinical practice is guided by clinical experience, consensus and research in other settings. Some research to compare haloperidol with other antiemetics is underway, however this is a relatively under-researched area. Nausea and vomiting are common, distressing symptoms with a profound impact on quality of life. Further studies are needed to determine the most effective strategies for managing these symptoms.</P>
</SUBSECTION>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2015-10-03 12:01:44 +0100" MODIFIED_BY="[Empty name]">
<P>Much has been written about methodological challenges when conducting research in palliative medicine (<LINK REF="REF-Jordhoy-1999" TYPE="REFERENCE">Jordhoy 1999</LINK>; <LINK REF="REF-Ewing-2004" TYPE="REFERENCE">Ewing 2004</LINK>). Nevertheless, two trials of haloperidol compared with other antiemetics are underway (<LINK REF="STD-ACTRN12610000481077" TYPE="STUDY">ACTRN12610000481077</LINK>; <LINK REF="STD-ACTRN12615000177550" TYPE="STUDY">ACTRN12615000177550</LINK>).</P>
<P>There is scope to build on this evidence further, using variations in intervention (e.g. dose, route of administration) and variations in trial design.</P>
<P>For instance, a randomised controlled trial could be conducted with participants with advanced disease who have nausea or vomiting, not associated with surgery, chemotherapy, radiotherapy or pregnancy, using an intervention of haloperidol, compared with another antiemetic, for example levomepromazine. Oral or subcutaneous routes of administration could be appropriate as these are often used in palliative care settings. Suggested outcomes include relief from nausea and from vomiting, anxiety, sedation, and extrapyramidal side effects. The duration of the study would be likely to have an impact on recruitment and attrition rates, but some side effects may only be apparent after weeks or months of use.</P>
<P>The pros and cons of placebo-controlled studies have been debated (<LINK REF="REF-Hardy-1997" TYPE="REFERENCE">Hardy 1997</LINK>; <LINK REF="REF-Kirkham-1997" TYPE="REFERENCE">Kirkham 1997</LINK>; <LINK REF="REF-Sanderson-2013" TYPE="REFERENCE">Sanderson 2013</LINK>). Placebo effects are likely to be significant, particularly in the context of a therapeutic relationship and environment (<LINK REF="REF-Sanderson-2013" TYPE="REFERENCE">Sanderson 2013</LINK>). Kris et al recommended that further trials of antiemetics in the context of chemotherapy should be conducted using active agents rather than placebo as comparator (<LINK REF="REF-Kris-1996" TYPE="REFERENCE">Kris 1996</LINK>). However a recent study of antiemetics in the emergency department compared metoclopramide, ondansetron and placebo and found no significant difference; most participants were satisfied with the treatment of their nausea (<LINK REF="REF-Egerton_x002d_Warburton-2014" TYPE="REFERENCE">Egerton-Warburton 2014</LINK>). The feasibility and ethical acceptability of a placebo arm may in part depend on the participants' perception of the severity of their symptoms and the urgency of the need for treatment.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2015-10-13 12:20:23 +0100" MODIFIED_BY="Anna Hobson">
<P>With thanks to Paul Perkins for his significant contributions to the original systematic review, Yvonne Roy and colleagues in the Cochrane Pain, Palliative &amp; Supportive Care Review Group, Sylvia Bickley for help with refining the search strategy and two review authors for their comments on an earlier draft of the protocol. Thanks also to Karen Rigby (Hinchingbrooke Hospital NHS Foundation Trust) who helped with some literature searching, Beccy Day who helped input some references and Jo Abbott, Caroline Struthers and Jane Hayes for helping us bring the literature search up to date.</P>
<P>Cochrane Review Group funding acknowledgement: The National Institute for Health Research (NIHR) is the largest single funder of the Cochrane PaPaS Group. Disclaimer: The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the NIHR, National Health Service (NHS) or the Department of Health.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2015-06-03 06:55:20 +0100" MODIFIED_BY="[Empty name]">
<P>FMB has no known conflicts of interest to declare that are relevant to the development of this review.</P>
<P>SD has no known conflicts of interest to declare that are relevant to the development of this review.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2015-06-03 08:01:36 +0100" MODIFIED_BY="[Empty name]">
<P>Paul Perkins and SD designed the original systematic review and wrote the protocol. SD developed the search strategy with comments from PP and advice from Sylvia Bickley. Both authors independently reviewed all titles and abstracts yielded by the search strategy for inclusion or exclusion and achieved a consensus by discussion (PP and SD for the original review, FM-B and SD for the updated review). FM-B and SD updated the text of the full review, which was originally written by PP and SD. SD is responsible for further updates.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2015-07-17 21:17:20 +0100" MODIFIED_BY="[Empty name]">
<P>We had planned to use the Jadad score (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>) to assess risk of bias but used the Cochrane risk of bias table instead, as recommended by the Cochrane Collaboration.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2017-05-04 16:15:33 +0100" MODIFIED_BY="Anna Erskine">
<P>A restricted search in May 2017 did not identify any potentially relevant studies likely to change the conclusions. Therefore, this review has now been stabilised following discussion with the authors and editors. We are aware of one relevant ongoing study, which we will assess when available. We will update the review if new evidence likely to change the conclusions is published, or if standards change substantially which necessitate major revisions.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2017-05-05 12:04:02 +0100" MODIFIED_BY="Anna Erskine">
<STUDIES MODIFIED="2015-10-03 12:01:44 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2015-10-03 11:57:46 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Fletcher-2014" MODIFIED="2015-10-03 11:57:46 +0100" MODIFIED_BY="[Empty name]" NAME="Fletcher 2014" YEAR="2014">
<REFERENCE MODIFIED="2015-10-03 11:57:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fletcher DS, Coyne PJ, Dodson PW, Parker GG, Wan W, Smith TJ</AU>
<TI>A randomized trial of the effectiveness of eopical "ABH Gel" (Ativan®, Benadryl®, Haldol®) vs. placebo in cancer patients with nausea</TI>
<SO>Journal of Pain and Symptom Management</SO>
<YR>2014</YR>
<VL>48</VL>
<NO>5</NO>
<PG>797-803</PG>
<IDENTIFIERS MODIFIED="2015-03-18 10:17:41 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836741"/><IDENTIFIER MODIFIED="2015-03-18 10:17:41 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1016/j.jpainsymman.2014.02.010"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836740"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2015-10-03 11:59:04 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Abdelsayed-2007" MODIFIED="2014-08-11 15:20:21 +0100" MODIFIED_BY="[Empty name]" NAME="Abdelsayed 2007" YEAR="2007">
<REFERENCE MODIFIED="2014-08-11 15:20:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abdelsayed G</AU>
<TI>Management of radiation-induced nausea and vomiting</TI>
<SO>Experimental Haematology</SO>
<YR>2007</YR>
<VL>35</VL>
<NO>4 Suppl</NO>
<PG>34-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836743"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836742"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bleicher-2008" MODIFIED="2014-08-11 16:00:30 +0100" MODIFIED_BY="[Empty name]" NAME="Bleicher 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-08-11 16:00:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bleicher J, Bhaskara A, Huyck T, Constantino S, Bardia A, Loprinzi CL, et al</AU>
<TI>Lorazepam, diphenhydramine, and haloperidol transdermal gel for rescue from chemotherapy-induced nausea and vomiting: Results of two pilot trials</TI>
<SO>Journal of Supportive Oncology</SO>
<YR>2008</YR>
<VL>6</VL>
<NO>1</NO>
<PG>27-32</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836745"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836744"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bregni-1991" MODIFIED="2014-08-11 16:00:33 +0100" MODIFIED_BY="[Empty name]" NAME="Bregni 1991" YEAR="1991">
<REFERENCE MODIFIED="2014-08-11 16:00:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bregni M, Siena S, Di Nicola M, Bonadonna G, Gianni AM</AU>
<TI>Tropisetron plus haloperidol to ameliorate nausea and vomiting associated with high-dose alkylating agent cancer chemotherapy</TI>
<SO>European Journal of Cancer</SO>
<YR>1991</YR>
<VL>27</VL>
<NO>5</NO>
<PG>561-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836747"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836746"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Buttner-2004" MODIFIED="2008-10-10 16:22:15 +0100" MODIFIED_BY="Jessica R Thomas" NAME="Buttner 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-10-10 16:22:15 +0100" MODIFIED_BY="Jessica R Thomas" NOTES="Anesthesiology. 2004 Dec; 101(6): 1454-63. (38 ref)" NOTES_MODIFIED="2008-10-10 16:22:15 +0100" NOTES_MODIFIED_BY="Jessica R Thomas" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buttner M, Walder B, von Elm E, Tramer MR</AU>
<TI>Is low-dose haloperidol a useful antiemetic? A meta-analysis of published and unpublished randomized trials</TI>
<SO>Anaesthesiology</SO>
<YR>2004</YR>
<VL>101</VL>
<PG>1454-63</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836749"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836748"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Casey-2011" MODIFIED="2014-08-11 16:00:41 +0100" MODIFIED_BY="[Empty name]" NAME="Casey 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-08-11 16:00:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Casey C, Chen LM, Rabow MW</AU>
<TI>Symptom management in gynaecologic malignancies</TI>
<SO>Expert Review of Anticancer Therapy</SO>
<YR>2011</YR>
<VL>11</VL>
<NO>7</NO>
<PG>1077-89</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836751"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836750"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cerchietti-2000" MODIFIED="2008-10-10 11:49:01 +0100" MODIFIED_BY="[Empty name]" NAME="Cerchietti 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-09-05 17:15:42 +0100" MODIFIED_BY="[Empty name]" NOTES="International Journal of Palliative Nursing 2000 Sep;6(8):370-4." NOTES_MODIFIED="2008-09-05 17:15:42 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cerchietti L, Navigante A, Sauri A, Palazzo F</AU>
<TI>Hypodermoclysis for control of dehydration in terminal-stage cancer</TI>
<SO>International Journal of Palliative Nursing</SO>
<YR>2000</YR>
<VL>6</VL>
<NO>8</NO>
<PG>370-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836753"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836752"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cheung-2011" MODIFIED="2014-04-06 11:54:23 +0100" MODIFIED_BY="[Empty name]" NAME="Cheung 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-04-06 11:54:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cheung W, Zimmerman C</AU>
<TI>Pharmacologic management of cancer-related pain, dyspnoea and nausea</TI>
<SO>Seminars in Oncology</SO>
<YR>2011</YR>
<VL>38</VL>
<NO>3</NO>
<PG>450-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836755"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836754"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chiu-2007" MODIFIED="2014-04-06 11:55:09 +0100" MODIFIED_BY="[Empty name]" NAME="Chiu 2007" YEAR="2007">
<REFERENCE MODIFIED="2014-04-06 11:55:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chiu W</AU>
<TI>Update on antiemetics of chemotherapy</TI>
<SO>Journal of Internal Medicine of Taiwan</SO>
<YR>2007</YR>
<VL>18</VL>
<NO>6</NO>
<PG>342-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836757"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836756"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chow-2010" MODIFIED="2014-08-11 16:00:49 +0100" MODIFIED_BY="[Empty name]" NAME="Chow 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-08-11 16:00:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chow C, Leung AK, Hon KL</AU>
<TI>Acute gastroenteritis: from guidelines to real life</TI>
<SO>Clinical and Experimental Gastroenterology</SO>
<YR>2010</YR>
<VL>3</VL>
<NO>1</NO>
<PG>97-112</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836759"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836758"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Christman-1974" MODIFIED="2008-10-10 16:22:30 +0100" MODIFIED_BY="Jessica R Thomas" NAME="Christman 1974" YEAR="1974">
<REFERENCE MODIFIED="2008-10-10 16:22:30 +0100" MODIFIED_BY="Jessica R Thomas" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Christman RS, Weinstein RA, Larose JB</AU>
<TI>Low-dose haloperidol as antiemetic treatment in gastrointestinal disorders: a double-blind study</TI>
<SO>Current Therapeutic Research</SO>
<YR>1974</YR>
<VL>16</VL>
<NO>11</NO>
<PG>1171-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836761"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836760"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Christo-2003" MODIFIED="2008-10-10 11:53:26 +0100" MODIFIED_BY="[Empty name]" NAME="Christo 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-10-10 11:52:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Christo PJ</AU>
<TI>Opioid effectiveness and side effects in chronic pain</TI>
<SO>Anesthesiology Clinics of North America</SO>
<YR>2003</YR>
<VL>21</VL>
<PG>699-713</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836763"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836762"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clary-2009" MODIFIED="2014-04-06 11:57:17 +0100" MODIFIED_BY="[Empty name]" NAME="Clary 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-04-06 11:57:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clary P, Lawson P</AU>
<TI>Pharmacologic pearls for end of life care</TI>
<SO>American Family Physician</SO>
<YR>2009</YR>
<VL>79</VL>
<NO>12</NO>
<PG>1059-65</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836765"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836764"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cole-1974" MODIFIED="2014-08-11 16:00:56 +0100" MODIFIED_BY="[Empty name]" NAME="Cole 1974" YEAR="1974">
<REFERENCE MODIFIED="2014-08-11 16:00:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cole DR, Duffy DF</AU>
<TI>Haloperidol for radiation sickness: control of associated nausea, vomiting, and anorexia</TI>
<SO>New York State Journal of Medicine</SO>
<YR>1974</YR>
<VL>74</VL>
<NO>9</NO>
<PG>1558-662</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836767"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836766"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cole-1994" MODIFIED="2008-10-10 16:23:23 +0100" MODIFIED_BY="Jessica R Thomas" NAME="Cole 1994" YEAR="1994">
<REFERENCE MODIFIED="2008-10-10 16:23:23 +0100" MODIFIED_BY="Jessica R Thomas" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cole RM, Robinson F, Harvey L, Trethowan K, Murdoch B</AU>
<TI>Successful control of intractable nausea and vomiting requiring combined ondansetron and haloperidol in a patient with advanced cancer</TI>
<SO>Journal of Pain and Symptom Management</SO>
<YR>1994</YR>
<VL>9</VL>
<PG>48-50</PG>
<IDENTIFIERS MODIFIED="2008-10-10 16:23:23 +0100" MODIFIED_BY="Jessica R Thomas"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836769"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836768"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Davis-2010" MODIFIED="2014-04-06 11:58:27 +0100" MODIFIED_BY="[Empty name]" NAME="Davis 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-04-06 11:58:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davis M, Hallerberg G</AU>
<TI>A systematic review of the treatment of nausea and/or vomiting in cancer unrelated to chemotherapy of radiation</TI>
<SO>Journal of Pain and Symptom Management</SO>
<YR>2010</YR>
<VL>39</VL>
<NO>4</NO>
<PG>756-67</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836771"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836770"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Vries-1969" MODIFIED="2008-10-08 17:27:32 +0100" MODIFIED_BY="[Empty name]" NAME="De Vries 1969" YEAR="1969">
<REFERENCE MODIFIED="2008-10-08 17:27:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Vries PM</AU>
<TI>A double-blind cross-over clinical valuation of metoclopramide and a combination of haloperidol and isopropamide iodide in gastroenterology</TI>
<SO>Arzneimittel-Forschung</SO>
<YR>1969</YR>
<VL>19</VL>
<PG>1766-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836773"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836772"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-DiVall-2007" MODIFIED="2014-04-06 11:59:18 +0100" MODIFIED_BY="[Empty name]" NAME="DiVall 2007" YEAR="2007">
<REFERENCE MODIFIED="2014-04-06 11:59:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>DiVall M, Cervosimo R</AU>
<TI>Prevention and treatment of chemotherapy-induced nausea and vomiting</TI>
<SO>Formulary</SO>
<YR>2007</YR>
<VL>42</VL>
<NO>6</NO>
<PG>378-88</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836775"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836774"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ettinger-2007" MODIFIED="2009-01-22 09:59:54 +0000" MODIFIED_BY="Jessica R Thomas" NAME="Ettinger 2007" YEAR="2007">
<REFERENCE MODIFIED="2008-10-14 17:12:33 +0100" MODIFIED_BY="Jessica R Thomas" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ettinger DS, Bierman PJ, Bradbury B, Comish CC, Ellis G, Ignoffo RJ, et al</AU>
<TI>Antiemesis: clinical practice guidelines in oncology</TI>
<SO>Journal of the National Comprehensive Cancer Network</SO>
<YR>2007</YR>
<VL>5</VL>
<PG>12-33</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836777"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-01-22 09:59:54 +0000" MODIFIED_BY="Jessica R Thomas"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836776"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ettinger-2009" MODIFIED="2014-08-11 16:01:08 +0100" MODIFIED_BY="[Empty name]" NAME="Ettinger 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-08-11 16:01:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ettinger D, Armstrong DK, Barbour S, Berger MJ, Bierman PJ, Bradbury B, et al</AU>
<TI>Antiemesis</TI>
<SO>Journal of the National Comprehensive Cancer Network</SO>
<YR>2009</YR>
<VL>7</VL>
<NO>5</NO>
<PG>572-95</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836779"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836778"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Feyer-2011" MODIFIED="2014-08-11 16:01:15 +0100" MODIFIED_BY="[Empty name]" NAME="Feyer 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-08-11 16:01:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Feyer P, Jordan K</AU>
<TI>Update and new trends in antiemetic therapy: the continuing need for novel therapies</TI>
<SO>Annals of Oncology</SO>
<YR>2011</YR>
<VL>22</VL>
<NO>1</NO>
<PG>30-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836781"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836780"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Findlay-1993" MODIFIED="2014-08-11 16:01:21 +0100" MODIFIED_BY="[Empty name]" NAME="Findlay 1993" YEAR="1993">
<REFERENCE MODIFIED="2014-08-11 16:01:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Findlay M, Simes RJ, Cox K, Carmichael K, Chey T, McNeil E, et al</AU>
<TI>A randomised cross-over trial of antiemetic therapy for platinum-based chemotherapy. Improved control with an intensive multiagent regimen</TI>
<SO>European Journal of Cancer</SO>
<YR>1993</YR>
<VL>29A</VL>
<NO>3</NO>
<PG>309-15</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836783"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836782"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fischberg-2007" MODIFIED="2014-04-06 12:02:15 +0100" MODIFIED_BY="[Empty name]" NAME="Fischberg 2007" YEAR="2007">
<REFERENCE MODIFIED="2014-04-06 12:02:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fischberg D</AU>
<TI>Randomised controlled trial of three antiemetics in the emergency department</TI>
<SO>Journal of Pain and Palliative Care Pharmacotherapy</SO>
<YR>2007</YR>
<VL>21</VL>
<NO>1</NO>
<PG>73-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836785"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836784"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Getto-2011" MODIFIED="2014-08-11 16:01:29 +0100" MODIFIED_BY="[Empty name]" NAME="Getto 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-08-11 16:01:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Getto L, Zeserson E, Breyer M</AU>
<TI>Vomiting, diarrhoea, constipation and gastroenteritis</TI>
<SO>Emergency Medicine Clinics of North America</SO>
<YR>2011</YR>
<VL>29</VL>
<NO>2</NO>
<PG>211-37</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836787"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836786"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Glare-2004" MODIFIED="2008-10-10 11:58:15 +0100" MODIFIED_BY="[Empty name]" NAME="Glare 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-09-05 17:16:36 +0100" MODIFIED_BY="[Empty name]" NOTES="Supportive Care in Cancer 2004 Jun;12(6):432-40." NOTES_MODIFIED="2008-09-05 17:16:36 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Glare P, Pereira G, Kristjanson LJ, Stockler M, Tattersall M</AU>
<TI>Systematic review of the efficacy of antiemetics in the treatment of nausea in patients with far-advanced cancer</TI>
<SO>Supportive Care Cancer</SO>
<YR>2004</YR>
<VL>12</VL>
<PG>432-40</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836789"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836788"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Glare-2011" MODIFIED="2014-08-11 16:01:38 +0100" MODIFIED_BY="[Empty name]" NAME="Glare 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-08-11 16:01:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Glare P, Miller J, Nikolova T, Tickoo R</AU>
<TI>Treating nausea and vomiting in palliative care: a review</TI>
<SO>Clinical Interventions in Ageing</SO>
<YR>2011</YR>
<VL>6</VL>
<NO>1</NO>
<PG>243-59</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836791"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836790"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gonzales-2011" MODIFIED="2014-04-06 12:04:35 +0100" MODIFIED_BY="[Empty name]" NAME="Gonzales 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-04-06 12:04:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gonzales M, Widera E</AU>
<TI>Nausea and other nonpain symptoms in long-term care</TI>
<SO>Clinics in Geriatric Medicine</SO>
<YR>2011</YR>
<VL>27</VL>
<NO>2</NO>
<PG>213-28</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836793"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836792"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grunberg-1984" MODIFIED="2008-10-10 16:26:09 +0100" MODIFIED_BY="Jessica R Thomas" NAME="Grunberg 1984" YEAR="1984">
<REFERENCE MODIFIED="2008-10-10 16:26:09 +0100" MODIFIED_BY="Jessica R Thomas" NOTES="Journal of Clinical Oncology. Vol. 2(7)(pp 782-787), 1984." NOTES_MODIFIED="2008-10-10 16:26:09 +0100" NOTES_MODIFIED_BY="Jessica R Thomas" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grunberg SM, Gala KV, Lampenfeld M, Jamin D, Johnson K, Cariffe P, et al</AU>
<TI>Comparison of the antiemetic effect of high-dose intravenous metoclopramide and high-dose intravenous haloperidol in a randomized double-blind crossover study</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1984</YR>
<VL>2</VL>
<NO>7</NO>
<PG>782-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836795"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836794"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grunberg-2010" MODIFIED="2014-08-11 16:01:49 +0100" MODIFIED_BY="[Empty name]" NAME="Grunberg 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-08-11 16:01:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grunberg S, Clark-Snow RA, Koeller J</AU>
<TI>Chemotherapy-induced nausea and vomiting: contemporary approaches to optimal management</TI>
<SO>Supportive Care in Cancer</SO>
<YR>2010</YR>
<VL>18 Suppl 1</VL>
<PG>S1-10</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836797"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836796"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hardy-2010" MODIFIED="2014-08-11 15:31:48 +0100" MODIFIED_BY="[Empty name]" NAME="Hardy 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-08-11 15:31:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hardy J, O'Shea A, White C, Gilshenan K, Welch L, Douglas C</AU>
<TI>The efficacy of haloperidol in the management of nausea and vomiting in patients with cancer</TI>
<SO>Journal of Pain and Symptom Management</SO>
<YR>2010</YR>
<VL>40</VL>
<NO>1</NO>
<PG>111-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836799"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836798"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Herndon-2002" MODIFIED="2008-10-10 16:26:19 +0100" MODIFIED_BY="Jessica R Thomas" NAME="Herndon 2002" YEAR="">
<REFERENCE MODIFIED="2008-10-10 16:26:19 +0100" MODIFIED_BY="Jessica R Thomas" NOTES="Pharmacotherapy. Vol. 22(2 I)(pp 240-250), 2002." NOTES_MODIFIED="2008-10-10 16:26:19 +0100" NOTES_MODIFIED_BY="Jessica R Thomas" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Herndon CM, Jackson IK, Hallin PA</AU>
<TI>Management of opioid-induced gastrointestinal effects in patients receiving palliative care</TI>
<SO>Pharmacotherapy</SO>
<YR>2002</YR>
<VL>22</VL>
<PG>240-50</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836801"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836800"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Herrstedt-2008" MODIFIED="2014-08-11 15:32:26 +0100" MODIFIED_BY="[Empty name]" NAME="Herrstedt 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-08-11 15:32:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Herrstedt J</AU>
<TI>Antiemetics: an update and the MASCC guidelines applied in clinical practice</TI>
<SO>Nature Clinical Practice Oncology</SO>
<YR>2008</YR>
<VL>5</VL>
<NO>1</NO>
<PG>32-43</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836803"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836802"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jordan-2007" MODIFIED="2014-08-11 15:33:04 +0100" MODIFIED_BY="[Empty name]" NAME="Jordan 2007" YEAR="2007">
<REFERENCE MODIFIED="2014-08-11 15:33:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jordan K, Schmoll HJ, Aapro MS</AU>
<TI>Comparative activity of anti-emetic drugs</TI>
<SO>Critical Reviews in Oncology/Hematology</SO>
<YR>2007</YR>
<VL>61</VL>
<NO>2</NO>
<PG>162-75</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836805"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836804"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kohara-2005" MODIFIED="2008-10-10 12:00:46 +0100" MODIFIED_BY="[Empty name]" NAME="Kohara 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-09-05 17:20:07 +0100" MODIFIED_BY="[Empty name]" NOTES="Journal of Palliative Medicine 2005 Feb;8(1):20-5." NOTES_MODIFIED="2008-09-05 17:20:07 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kohara H, Ueoka H, Takeyama H, Murakami T, Morita T</AU>
<TI>Sedation for terminally ill patients with cancer with uncontrollable physical distress</TI>
<SO>Journal of Palliative Medicine</SO>
<YR>2005</YR>
<VL>8</VL>
<NO>1</NO>
<PG>20-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836807"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836806"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ladabaum-1999" MODIFIED="2008-10-10 12:01:09 +0100" MODIFIED_BY="[Empty name]" NAME="Ladabaum 1999" YEAR="1999">
<REFERENCE MODIFIED="2008-09-05 17:23:05 +0100" MODIFIED_BY="[Empty name]" NOTES="Digestive Diseases. Vol. 17(3)(pp 125-132), 1999." NOTES_MODIFIED="2008-09-05 17:23:05 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ladabaum U, Hasler WL</AU>
<TI>Novel approaches to the treatment of nausea and vomiting</TI>
<SO>Digestive Diseases</SO>
<YR>1999</YR>
<VL>17</VL>
<PG>125-32</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836809"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836808"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liem_x002d_Moolenar-2010" MODIFIED="2014-08-11 15:34:09 +0100" MODIFIED_BY="[Empty name]" NAME="Liem-Moolenar 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-08-11 15:34:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liem-Moolenaar M, te Beek ET, de Kam ML, Franson KL, Kahn RS, Hijman R, et al</AU>
<TI>Central nervous system effects of haloperidol on THC in healthy male volunteers</TI>
<SO>Journal of Psychopharmacology</SO>
<YR>2010</YR>
<VL>24</VL>
<NO>11</NO>
<PG>1697-708</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836811"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836810"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lohr-2008" MODIFIED="2014-04-06 12:10:00 +0100" MODIFIED_BY="[Empty name]" NAME="Lohr 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-04-06 12:10:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lohr L</AU>
<TI>Chemotherapy-induced nausea and vomiting</TI>
<SO>Cancer Journal</SO>
<YR>2008</YR>
<VL>14</VL>
<NO>2</NO>
<PG>85-93</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836813"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836812"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McHugh-2011" MODIFIED="2014-04-06 12:10:57 +0100" MODIFIED_BY="[Empty name]" NAME="McHugh 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-04-06 12:10:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McHugh M, Miller-Saultz D</AU>
<TI>Assessment of gastrointestinal symptoms in advanced illness</TI>
<SO>Primary Care - Clinics in Office Practice</SO>
<YR>2011</YR>
<VL>38</VL>
<NO>2</NO>
<PG>225-46</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836815"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836814"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McNicol-2003" MODIFIED="2014-08-11 15:34:50 +0100" MODIFIED_BY="[Empty name]" NAME="McNicol 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-08-11 15:34:50 +0100" MODIFIED_BY="[Empty name]" NOTES="Journal of Pain. Vol. 4(5)(pp 231-256), 2003." NOTES_MODIFIED="2014-08-11 15:34:50 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McNicol E, Horowicz-Mehler N, Fisk RA, Bennett K, Gialeli-Goudas M, Chew PW, et al</AU>
<TI>Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review</TI>
<SO>Journal of Pain</SO>
<YR>2003</YR>
<VL>4</VL>
<NO>5</NO>
<PG>231-56</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836817"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836816"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mercadante-2007" MODIFIED="2014-08-11 15:35:08 +0100" MODIFIED_BY="[Empty name]" NAME="Mercadante 2007" YEAR="2007">
<REFERENCE MODIFIED="2014-08-11 15:35:08 +0100" MODIFIED_BY="[Empty name]" NOTES="Journal of Pain &amp;amp; Symptom Management. Vol. 33(2)(pp 217-223), 2007." NOTES_MODIFIED="2014-08-11 15:35:08 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mercadante S, Casuccio A, Mangione S</AU>
<TI>Medical treatment for inoperable malignant bowel obstruction: a qualitative systematic review</TI>
<SO>Journal of Pain and Symptom Management</SO>
<YR>2007</YR>
<VL>33</VL>
<NO>2</NO>
<PG>217-23</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836819"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836818"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Naeim-2008" MODIFIED="2014-04-06 12:11:49 +0100" MODIFIED_BY="[Empty name]" NAME="Naeim 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-04-06 12:11:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Naeim A</AU>
<TI>Evidence-based recommendations for cancer nausea and vomiting</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2008</YR>
<VL>26</VL>
<NO>23</NO>
<PG>3903-10</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836821"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836820"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Navari-2007" MODIFIED="2014-08-11 15:35:34 +0100" MODIFIED_BY="[Empty name]" NAME="Navari 2007" YEAR="2007">
<REFERENCE MODIFIED="2014-08-11 15:35:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Navari M</AU>
<TI>Overview of the updated antiemetic guidelines for chemotherapy-induced nausea and vomiting</TI>
<SO>Community Oncology</SO>
<YR>2007</YR>
<VL>4 Suppl 1</VL>
<PG>3-11</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836823"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836822"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Neidhart-1981" MODIFIED="2014-08-11 15:35:42 +0100" MODIFIED_BY="[Empty name]" NAME="Neidhart 1981" YEAR="1981">
<REFERENCE MODIFIED="2014-08-11 15:35:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neidhart JA, Gagen M, Young DM, Wilson HE</AU>
<TI>Specific antiemetics for specific cancer chemotherapeutic agents: haloperidol versus benzquinamide</TI>
<SO>Cancer</SO>
<YR>1981</YR>
<VL>47</VL>
<PG>1439-43</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836825"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836824"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x0027_Connor-2011" MODIFIED="2014-04-06 12:13:38 +0100" MODIFIED_BY="[Empty name]" NAME="O'Connor 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-04-06 12:13:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O'Connor B, Creedon B</AU>
<TI>Pharmacological treatment of bowel obstruction in cancer patients</TI>
<SO>Expert Opinion on Pharmacotherapy</SO>
<YR>2011</YR>
<VL>12</VL>
<NO>14</NO>
<PG>2205-14</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836827"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836826"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Owens-1984" MODIFIED="2008-10-10 16:27:41 +0100" MODIFIED_BY="Jessica R Thomas" NAME="Owens 1984" YEAR="1984">
<REFERENCE MODIFIED="2008-10-10 16:27:41 +0100" MODIFIED_BY="Jessica R Thomas" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Owens NJ, Schauer AR, Nightingale CH, Golub GR, Martin RS, Williams HM, et al</AU>
<TI>Antiemetic efficacy of prochlorperazine, haloperidol, and droperidol in cisplatin-induced emesis</TI>
<SO>Clinical Pharmacy</SO>
<YR>1984</YR>
<VL>3</VL>
<PG>167-70</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836829"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836828"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Perkins-2009" MODIFIED="2014-08-11 16:57:32 +0100" MODIFIED_BY="[Empty name]" NAME="Perkins 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-08-11 16:57:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="COCHRANE_REVIEW">
<AU>Perkins P, Dorman S</AU>
<TI>Haloperidol for the treatment of nausea and vomiting in palliative care patients</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2014-08-11 16:57:32 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836831"/><IDENTIFIER MODIFIED="2014-08-11 16:57:32 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006271.pub2"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836830"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pleuvry-2009" MODIFIED="2014-04-06 12:15:20 +0100" MODIFIED_BY="[Empty name]" NAME="Pleuvry 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-04-06 12:15:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pleuvry B</AU>
<TI>Physiology and pharmacology of nausea and vomiting</TI>
<SO>Anaesthesia and Intensive Care Medicine</SO>
<YR>2009</YR>
<VL>10</VL>
<NO>12</NO>
<PG>597-601</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836833"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836832"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Porreca-2009" MODIFIED="2014-04-06 12:16:22 +0100" MODIFIED_BY="[Empty name]" NAME="Porreca 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-04-06 12:16:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Porreca F, Ossipov M</AU>
<TI>Nausea and vomiting side effects with opioid analgesics during treatment of chronic pain: Mechanisms, implications and management options</TI>
<SO>Pain Medicine</SO>
<YR>2009</YR>
<VL>10</VL>
<NO>4</NO>
<PG>654-62</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836835"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836834"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ripamonti-2001" MODIFIED="2008-10-10 16:27:49 +0100" MODIFIED_BY="Jessica R Thomas" NAME="Ripamonti 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-10-10 16:27:49 +0100" MODIFIED_BY="Jessica R Thomas" NOTES="Supportive Care in Cancer. Vol. 9(4)(pp 223-233), 2001." NOTES_MODIFIED="2008-10-10 16:27:49 +0100" NOTES_MODIFIED_BY="Jessica R Thomas" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ripamonti C, Twycross R, Baines M, Bozzetti F, Capri S, De Conno F, et al</AU>
<TI>Clinical-practice recommendations for the management of bowel obstruction in patients with end-stage cancer</TI>
<SO>Supportive Care in Cancer</SO>
<YR>2001</YR>
<VL>9</VL>
<PG>223-33</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836837"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836836"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Robbins-1975" MODIFIED="2014-08-11 15:38:23 +0100" MODIFIED_BY="[Empty name]" NAME="Robbins 1975" YEAR="1975">
<REFERENCE MODIFIED="2014-08-11 15:38:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Robbins EL, Nagel JD</AU>
<TI>Haloperidol parenterally for treatment of vomiting and nausea from gastrointestinal disorders in a group of geriatric patients: double-blind, placebo-controlled study</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>1975</YR>
<VL>23</VL>
<PG>38-41</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836839"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836838"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roeland-2010" MODIFIED="2014-08-11 15:39:23 +0100" MODIFIED_BY="[Empty name]" NAME="Roeland 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-08-11 15:39:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roeland E, Mitchell W, Elia G, Thornberry K, Herman H, Cain J, et al</AU>
<TI>Symptom control in stem cell transplantation: a multidisciplinary palliative care team approach. Part 1: Physical symptoms</TI>
<SO>Journal of Supportive Oncology</SO>
<YR>2010</YR>
<VL>8</VL>
<NO>3</NO>
<PG>100-16</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836841"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836840"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saller-1985" MODIFIED="2014-08-11 15:39:42 +0100" MODIFIED_BY="[Empty name]" NAME="Saller 1985" YEAR="1985">
<REFERENCE MODIFIED="2014-08-11 15:39:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saller R, Hellenbrecht D</AU>
<TI>The benefit and risk of high dose metoclopramide in comparison to high dose haloperidol or trifluorpromazine in cisplatin-induced emesis</TI>
<SO>Klinische Wochenschrift</SO>
<YR>1985</YR>
<VL>63</VL>
<PG>428-32</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836843"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836842"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Siden-2008" MODIFIED="2014-04-06 12:18:22 +0100" MODIFIED_BY="[Empty name]" NAME="Siden 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-04-06 12:18:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Siden H</AU>
<TI>Haloperidol as a palliative anti-emetic in a toddler: an evidence-base challenge</TI>
<SO>Journal of Pain and Symptom Management</SO>
<YR>2008</YR>
<VL>35</VL>
<NO>3</NO>
<PG>235-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836845"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836844"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Silvey-1988" MODIFIED="2014-08-11 15:40:37 +0100" MODIFIED_BY="[Empty name]" NAME="Silvey 1988" YEAR="1988">
<REFERENCE MODIFIED="2014-08-11 15:40:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Silvey L, Carpenter JT, Wheeler RH, Lee J, Conolley C</AU>
<TI>A randomized comparison of haloperidol plus dexamethasone versus prochlorperazine plus dexamethasone in preventing nausea and vomiting in patients receiving chemotherapy for breast cancer</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1988</YR>
<VL>6</VL>
<NO>9</NO>
<PG>1397-400</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836847"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836846"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-2011" MODIFIED="2014-08-11 15:44:00 +0100" MODIFIED_BY="[Empty name]" NAME="Smith 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-08-11 15:44:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith T, Ritter JK, Coyne PJ, Parker GL, Dodson P, Fletcher DS</AU>
<TI>Testing the cutaneous absorption of lorazepam, diphenhydramine and haloperidol gel (ABH gel) used for cancer-related nausea</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2011</YR>
<VL>29</VL>
<PG>Abstract 9021</PG>
<CY>Chicago</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836849"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836848"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-2012a" MODIFIED="2015-10-03 11:59:04 +0100" MODIFIED_BY="[Empty name]" NAME="Smith 2012a" YEAR="2012">
<REFERENCE MODIFIED="2015-10-03 11:59:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Smith T, Fletcher D, Coyne P, Dodson P, Parker G</AU>
<TI>ABH gel is not absorbed from the skin of normal volunteer so cannot be effective against nausea</TI>
<SO>Journal of Pain and Symptom Management. Conference: Annual Assembly of the American Academy of Hospice and Palliative Medicine and the Hospice and Palliative Nurses Association</SO>
<YR>2012</YR>
<CY>Denver, US</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836851"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836850"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sperry-2007" MODIFIED="2014-04-06 12:23:14 +0100" MODIFIED_BY="[Empty name]" NAME="Sperry 2007" YEAR="2007">
<REFERENCE MODIFIED="2014-04-06 12:23:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sperry M</AU>
<TI>A review of the 2006 ASCO antiemetic guidelines update</TI>
<SO>US Pharmacist</SO>
<YR>2007</YR>
<VL>32</VL>
<NO>1</NO>
<PG>22-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836853"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836852"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stapleton-2009" MODIFIED="2014-04-06 12:24:19 +0100" MODIFIED_BY="[Empty name]" NAME="Stapleton 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-04-06 12:24:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stapleton J, Wo J</AU>
<TI>Current treatment of nausea and vomiting associated with gastroparesis: antiemetics, prokinetics, tricyclics</TI>
<SO>Gastrointestinal Endoscopy Clinics of North America</SO>
<YR>2009</YR>
<VL>19</VL>
<NO>1</NO>
<PG>57-72</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836855"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836854"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tatum-2009" MODIFIED="2014-04-06 12:24:56 +0100" MODIFIED_BY="[Empty name]" NAME="Tatum 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-04-06 12:24:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tatum P</AU>
<TI>Haloperidol for nausea and vomiting</TI>
<SO>Journal of Pain and Palliative Care Pharmacotherapy</SO>
<YR>2009</YR>
<VL>23</VL>
<NO>4</NO>
<PG>426-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836857"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836856"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tornetta-1971" MODIFIED="2009-02-03 13:30:14 +0000" MODIFIED_BY="Jessica R Thomas" NAME="Tornetta 1971" YEAR="1971">
<REFERENCE MODIFIED="2009-02-03 13:30:14 +0000" MODIFIED_BY="Jessica R Thomas" NOTES="&lt;p&gt;JT: Could you check the question marks in this reference, don't think they're needed?&lt;/p&gt;" NOTES_MODIFIED="2009-02-03 13:30:14 +0000" NOTES_MODIFIED_BY="Jessica R Thomas" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tornetta FJ</AU>
<TI>Haloperidol as an antiemetic - guest discussion</TI>
<SO>Anesthesia and Analgesia - Current Researches</SO>
<YR>1971</YR>
<VL>50</VL>
<NO>6</NO>
<PG>1024-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836859"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836858"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tornetta-1972" MODIFIED="2008-10-10 16:29:28 +0100" MODIFIED_BY="Jessica R Thomas" NAME="Tornetta 1972" YEAR="1972">
<REFERENCE MODIFIED="2008-10-10 16:29:28 +0100" MODIFIED_BY="Jessica R Thomas" NOTES="&lt;p&gt;JT: Also this reference doesn't look quite right?&lt;/p&gt;" NOTES_MODIFIED="2008-10-10 16:29:28 +0100" NOTES_MODIFIED_BY="Jessica R Thomas" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tornetta FJ</AU>
<TI>Double-blind evaluation of haloperidol for antiemetic activity. Anesthesia and analgesia</TI>
<SO>Current Researches</SO>
<YR>1972</YR>
<VL>51</VL>
<NO>6</NO>
<PG>964-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836861"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-10-06 10:29:27 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836860"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Trigg-2008" MODIFIED="2014-08-11 15:51:04 +0100" MODIFIED_BY="[Empty name]" NAME="Trigg 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-08-11 15:51:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Trigg M, Inverso D</AU>
<TI>Nausea and vomiting with high-dose chemotherapy and stem cell rescue therapy: a review of antiemetic regimens</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>2008</YR>
<VL>42</VL>
<NO>8</NO>
<PG>501-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836863"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836862"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Trigg-2010" MODIFIED="2014-08-11 15:51:16 +0100" MODIFIED_BY="[Empty name]" NAME="Trigg 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-08-11 15:51:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Trigg M</AU>
<TI>Chemotherapy-induced nausea and vomiting: antiemetic trials that impacted clinical practice</TI>
<SO>Journal of Oncology Pharmacy Practice</SO>
<YR>2010</YR>
<VL>16</VL>
<NO>4</NO>
<PG>233-44</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836865"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836864"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weschules-2005" MODIFIED="2008-10-06 10:20:07 +0100" MODIFIED_BY="[Empty name]" NAME="Weschules 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-10-06 10:20:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weschules DJ</AU>
<TI>Tolerability of the compound ABHR in hospice patients</TI>
<SO>Journal of Palliative Medicine</SO>
<YR>2005</YR>
<VL>8</VL>
<NO>6</NO>
<PG>1135-43</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836867"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836866"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-White-2006" MODIFIED="2008-10-10 12:06:14 +0100" MODIFIED_BY="[Empty name]" NAME="White 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-09-05 17:27:18 +0100" MODIFIED_BY="[Empty name]" NOTES="Palliative Medicine 2006 Apr;20(3):215-6." NOTES_MODIFIED="2008-09-05 17:27:18 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>White C, McPherson A, McCann MA, Sadler A, Fyvie J</AU>
<TI>Prolonged extra-pyramidal side effects after discontinuation of haloperidol as an antiemetic</TI>
<SO>Palliative Medicine</SO>
<YR>2006</YR>
<VL>20</VL>
<PG>215-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836869"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836868"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2015-03-06 14:12:15 +0000" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2015-10-03 12:01:44 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-ACTRN12610000481077" MODIFIED="2015-10-03 12:01:44 +0100" MODIFIED_BY="[Empty name]" NAME="ACTRN12610000481077" YEAR="2010">
<REFERENCE MODIFIED="2015-08-25 08:40:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Hardy J, Yates P, Philip J, Martin P, Glare P, Currow D</AU>
<TI>A targeted versus empiric approach to antiemetic use in advanced cancer</TI>
<SO>In: MASCC/ISOO International Symposium on Supportive Care in Cancer</SO>
<YR>26 June 2014</YR>
<IDENTIFIERS MODIFIED="2015-08-25 08:40:47 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836871"/><IDENTIFIER MODIFIED="2015-08-25 08:40:47 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="http:/mascc2014.meetingxpert.net/MASCC_595/poster_96766/program.aspx/anchor96766"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-03-18 10:20:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="OTHER">
<AU>Yates P</AU>
<TI>The effectiveness of guideline driven antiemetic therapy versus single agent antiemetic therapy in patients with cancer and nausea not related to cancer therapy</TI>
<SO>Australian New Zealand Clinical Trials Registry</SO>
<YR>2010</YR>
<IDENTIFIERS MODIFIED="2015-03-18 10:19:27 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836872"/><IDENTIFIER MODIFIED="2014-10-15 11:09:53 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="ACTRN12610000481077"/><IDENTIFIER MODIFIED="2015-03-18 10:19:27 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12610000481077"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836870"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ACTRN12615000177550" MODIFIED="2015-10-03 12:00:30 +0100" MODIFIED_BY="[Empty name]" NAME="ACTRN12615000177550" YEAR="2015">
<REFERENCE MODIFIED="2015-10-03 12:00:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Hardy JR</AU>
<TI>A randomised, controlled, double blind study of oral methotrimeprazine versus oral haloperidol in patients with cancer and nausea not related to anticancer therapy (Nausea study 3), to compare the effectiveness of oral methotrimeprazine versus oral haloperidol in improving the management of nausea in patients with cancer and nausea not related to anticancer therapy</TI>
<SO>World Health Organization International Clinical Trials Registry Platform</SO>
<YR>23 February 2015</YR>
<IDENTIFIERS MODIFIED="2015-03-06 12:44:36 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2836874"/><IDENTIFIER MODIFIED="2015-03-06 12:43:29 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="ACTRN12615000177550"/><IDENTIFIER MODIFIED="2015-03-06 12:44:36 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="http://www.anzctr.org.au/ACTRN1261500077550.aspx"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2015-03-06 12:39:46 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2836873"/><IDENTIFIER MODIFIED="2015-03-06 12:38:40 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="ACTRN12615000177550"/><IDENTIFIER MODIFIED="2015-03-06 12:39:46 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="http://apps.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12615000177550"/></IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2015-10-03 13:14:18 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2015-10-03 13:14:18 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Barton-1975" MODIFIED="2009-01-27 12:30:54 +0000" MODIFIED_BY="[Empty name]" NAME="Barton 1975" TYPE="JOURNAL_ARTICLE">
<AU>Barton MD, Libonati M, Cohen PJ</AU>
<TI>The use of haloperidol for treatment of postoperative nausea and vomiting--a double-blind placebo-controlled trial</TI>
<SO>Anesthesiology</SO>
<YR>1975</YR>
<VL>42</VL>
<NO>4</NO>
<PG>508-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bentley-2001" NAME="Bentley 2001" TYPE="JOURNAL_ARTICLE">
<AU>Bentley A, Boyd K</AU>
<TI>Use of clinical pictures in the management of nausea and vomiting</TI>
<SO>Palliative Medicine</SO>
<YR>2001</YR>
<VL>15</VL>
<PG>247-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Critchley-2001" MODIFIED="2014-08-11 15:52:10 +0100" MODIFIED_BY="[Empty name]" NAME="Critchley 2001" TYPE="JOURNAL_ARTICLE">
<AU>Critchley P, Plach N, Grantham M, Marshall D, Taniguchi A, Latimer E, et al</AU>
<TI>Efficacy of haloperidol in the treatment of nausea and vomiting in the palliative patient: a systematic review</TI>
<SO>Journal of Pain and Symptom Management</SO>
<YR>2001</YR>
<VL>22</VL>
<PG>631-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Edmonds-2001" NAME="Edmonds 2001" TYPE="JOURNAL_ARTICLE">
<AU>Edmonds P, Karlsen S, Khan S, Addington-Hall J</AU>
<TI>A comparison of the palliative care needs of patients dying from chronic respiratory diseases and lung cancer</TI>
<SO>Palliative Medicine</SO>
<YR>2001</YR>
<VL>15</VL>
<PG>287-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egerton_x002d_Warburton-2014" MODIFIED="2015-06-03 07:31:40 +0100" MODIFIED_BY="[Empty name]" NAME="Egerton-Warburton 2014" TYPE="JOURNAL_ARTICLE">
<AU>Egerton-Warburton D, Meek R, Mee MJ, Braitberg G</AU>
<TI>Antiemetic use for nausea and vomiting in adult emergency department patients: randomized controlled trial comparing ondansetron, metoclopramide, and placebo</TI>
<SO>Annals of Emergency Medicine</SO>
<YR>2014</YR>
<VL>64</VL>
<NO>5</NO>
<PG>526-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ewing-2004" MODIFIED="2009-01-22 10:03:59 +0000" MODIFIED_BY="Jessica R Thomas" NAME="Ewing 2004" TYPE="JOURNAL_ARTICLE">
<AU>Ewing G, Rogers M, Barclays S, McCabe J, Martin A, Todd C</AU>
<TI>Recruiting patients into a primary care based study of palliative care: why is it so difficult?</TI>
<SO>Palliative Medicine</SO>
<YR>2004</YR>
<VL>18</VL>
<PG>452-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hardy-1997" MODIFIED="2015-06-03 07:37:50 +0100" MODIFIED_BY="[Empty name]" NAME="Hardy 1997" TYPE="JOURNAL_ARTICLE">
<AU>Hardy JR</AU>
<TI>Placebo-controlled trials in palliative care: the argument for</TI>
<SO>Palliative Medicine</SO>
<YR>1997</YR>
<VL>11</VL>
<NO>5</NO>
<PG>415-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2015-10-03 12:58:38 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557- 60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hirst-2001" MODIFIED="2014-08-11 15:52:37 +0100" MODIFIED_BY="[Empty name]" NAME="Hirst 2001" TYPE="COCHRANE_REVIEW">
<AU>Hirst A, Sloan R</AU>
<TI>Benzodiazepines and related drugs for insomnia in palliative care</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2008-07-01 10:45:16 +0100" MODIFIED_BY="Laila Tyrrell"><IDENTIFIER MODIFIED="2008-07-01 10:45:16 +0100" MODIFIED_BY="Laila Tyrrell" TYPE="DOI" VALUE="10.1002/14651858.CD003346"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" MODIFIED="2014-08-11 15:52:56 +0100" MODIFIED_BY="[Empty name]" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al</AU>
<TI>Assessing the quality of randomized clinical trials: is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jordhoy-1999" MODIFIED="2009-01-22 10:05:24 +0000" MODIFIED_BY="Jessica R Thomas" NAME="Jordhoy 1999" TYPE="JOURNAL_ARTICLE">
<AU>Jordhoy M, Kaasa S, Fayers P, Ovreness T, Underland G, Ahlner-Elmqvist M</AU>
<TI>Challenges in palliative care research; recruitment, attrition and compliance: experience from a randomized controlled trial</TI>
<SO>Palliative Medicine</SO>
<YR>1999</YR>
<VL>13</VL>
<PG>299-310</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Keeley-2007" MODIFIED="2009-01-22 10:06:03 +0000" MODIFIED_BY="Jessica R Thomas" NAME="Keeley 2007" TYPE="JOURNAL_ARTICLE">
<AU>Keeley P</AU>
<TI>Nausea and vomiting in people with cancer and other chronic diseases</TI>
<SO>BMJ Clinical Evidence</SO>
<YR>2007</YR>
<VL>06</VL>
<PG>2406</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kirkham-1997" MODIFIED="2015-06-03 07:36:19 +0100" MODIFIED_BY="[Empty name]" NAME="Kirkham 1997" TYPE="JOURNAL_ARTICLE">
<AU>Kirkham SR, Abel J</AU>
<TI>Placebo-controlled trials in palliative care: the argument against</TI>
<SO>Palliative Medicine</SO>
<YR>1997</YR>
<VL>11</VL>
<NO>6</NO>
<PG>489-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Klinkenberg-2004" NAME="Klinkenberg 2004" TYPE="JOURNAL_ARTICLE">
<AU>Klinkenberg M, Willems DL, van der Wal G, Deeg DJH</AU>
<TI>Symptom burden in the last week of life</TI>
<SO>Journal of Pain and Symptom Management</SO>
<YR>2004</YR>
<VL>27</VL>
<PG>5-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kris-1996" MODIFIED="2015-06-03 07:28:14 +0100" MODIFIED_BY="[Empty name]" NAME="Kris 1996" TYPE="JOURNAL_ARTICLE">
<AU>Kris MG, Cubeddu LX, Gralla RJ, Cupissol D, Tyson LB, Venkatraman E, Homesley HD</AU>
<TI>Are more antiemetic trials with a placebo necessary? Report of patient data from randomized trials of placebo antiemetics with cisplatin</TI>
<SO>Cancer</SO>
<YR>1996</YR>
<VL>78</VL>
<NO>10</NO>
<PG>2193-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lindqvist-2013" MODIFIED="2014-08-11 15:53:56 +0100" MODIFIED_BY="[Empty name]" NAME="Lindqvist 2013" TYPE="JOURNAL_ARTICLE">
<AU>Lindqvist O, Lundquist G, Dickman A, Bükki J, Lunder U, Hagelin CL, et al</AU>
<TI>Four essential drugs needed for quality care of the dying: a Delphi-study based international expert consensus opinion</TI>
<SO>Journal of Palliative Medicine</SO>
<YR>2013</YR>
<VL>16</VL>
<NO>1</NO>
<PG>38-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-L_x2019_Abb_x00e9_-1987" MODIFIED="2015-05-31 19:46:37 +0100" MODIFIED_BY="[Empty name]" NAME="L&#8217;Abbé 1987" TYPE="JOURNAL_ARTICLE">
<AU>L&#8217;Abbé KA, Detsky AS, O&#8217;Rourke K</AU>
<TI>Meta-analysis in clinical research</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1987</YR>
<VL>107</VL>
<PG>224-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mannix-2004" NAME="Mannix 2004" TYPE="BOOK_SECTION">
<AU>Mannix KA</AU>
<TI>Palliation of nausea and vomiting</TI>
<SO>Oxford Textbook of Palliative Medicine</SO>
<YR>2004</YR>
<PB>Oxford University Press</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McLean-2013" MODIFIED="2014-08-11 15:54:39 +0100" MODIFIED_BY="[Empty name]" NAME="McLean 2013" TYPE="JOURNAL_ARTICLE">
<AU>McLean SL, Blenkinsopp A, Bennett MI</AU>
<TI>Using haloperidol as an antiemetic in palliative care: informing practice through evidence from cancer treatment and postoperative contexts</TI>
<SO>Journal of Pain and Palliative Care Pharmacotherapy</SO>
<YR>2013</YR>
<VL>27</VL>
<NO>2</NO>
<PG>132-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Miller-2008" MODIFIED="2014-08-11 15:55:09 +0100" MODIFIED_BY="[Empty name]" NAME="Miller 2008" TYPE="JOURNAL_ARTICLE">
<AU>Miller JL, Ashford JW, Archer SM, Rudy AC, Wermeling DP</AU>
<TI>Comparison of intranasal administration of haloperidol with intravenous and intramuscular administration</TI>
<SO>Pharmacotherapy</SO>
<YR>2008</YR>
<VL>28</VL>
<NO>7</NO>
<PG>875-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pereira-2012" MODIFIED="2015-03-06 12:18:13 +0000" MODIFIED_BY="[Empty name]" NAME="Pereira 2012" TYPE="OTHER">
<AU>Pereira J</AU>
<TI>Study comparing olanzapine with haloperidol for the relief of nausea and vomiting in patients with advanced cancer</TI>
<SO>clinicaltrials.gov</SO>
<IDENTIFIERS MODIFIED="2015-03-06 12:17:53 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2015-03-06 12:17:53 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="ISRCTN58624349"/><IDENTIFIER MODIFIED="2015-03-06 12:12:17 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="NCT00124930"/><IDENTIFIER MODIFIED="2015-03-06 12:13:21 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="https://clinicaltrials.gov/ct2/show/NCT00124930?term=Haloperidol&amp;rank=59"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Prommer-2012" MODIFIED="2014-04-06 11:48:47 +0100" MODIFIED_BY="[Empty name]" NAME="Prommer 2012" TYPE="JOURNAL_ARTICLE">
<AU>Prommer E</AU>
<TI>Role of haloperidol in palliative medicine: an update</TI>
<SO>American Journal of Hospice and Palliative Medicine</SO>
<YR>2012</YR>
<VL>29</VL>
<NO>4</NO>
<PG>295-301</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reuben-1986" MODIFIED="2015-10-03 12:59:26 +0100" MODIFIED_BY="[Empty name]" NAME="Reuben 1986" TYPE="JOURNAL_ARTICLE">
<AU>Reuben DB, Mor V</AU>
<TI>Nausea and vomiting in terminal cancer patients</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1986</YR>
<VL>146</VL>
<PG>2021-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2014" MODIFIED="2014-08-11 16:02:33 +0100" MODIFIED_BY="[Empty name]" NAME="RevMan 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sanderson-2013" MODIFIED="2015-06-03 07:43:01 +0100" MODIFIED_BY="[Empty name]" NAME="Sanderson 2013" TYPE="JOURNAL_ARTICLE">
<AU>Sanderson C, Hardy J, Spruyt O, Currow DC</AU>
<TI>Placebo and nocebo effects in randomized controlled trials: the implications for research and practice</TI>
<SO>Journal of Pain and Symptom Management</SO>
<YR>2013</YR>
<VL>46</VL>
<NO>5</NO>
<PG>722-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sch_x00fc_nemann-2011" MODIFIED="2015-10-03 13:13:34 +0100" MODIFIED_BY="[Empty name]" NAME="Schünemann 2011" TYPE="OTHER">
<AU>Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH</AU>
<TI>Chapter 11: Presenting results and &#8216;Summary of findings' tables. In: Higgins JPT, Green S (editors), <I>Cochrane Handbook for Systematic Reviews of Interventions</I> Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Smith-2012b" MODIFIED="2015-08-23 16:43:28 +0100" MODIFIED_BY="Denise M Mitchell" NAME="Smith 2012b" TYPE="JOURNAL_ARTICLE">
<AU>Smith HR, Cox LR, Smith BR</AU>
<TI>Dopamine receptor antagonists</TI>
<SO>Annals of Palliative Medicine</SO>
<YR>2012</YR>
<VL>1</VL>
<NO>2</NO>
<PG>137-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Solano-2006" MODIFIED="2015-05-31 18:07:10 +0100" MODIFIED_BY="[Empty name]" NAME="Solano 2006" TYPE="JOURNAL_ARTICLE">
<AU>Solano JP, Gomes B, Higginson IJ</AU>
<TI>A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease</TI>
<SO>Journal of Pain and Symptom Management</SO>
<YR>2006</YR>
<VL>31</VL>
<NO>1</NO>
<PG>58-69</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Susman-2001" MODIFIED="2014-08-11 15:55:42 +0100" MODIFIED_BY="[Empty name]" NAME="Susman 2001" TYPE="JOURNAL_ARTICLE">
<AU>Susman VL</AU>
<TI>Clinical management of neuroleptic malignant syndrome</TI>
<SO>Psychiatric Quarterly</SO>
<YR>2001</YR>
<VL>72</VL>
<PG>325-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-To-2014" MODIFIED="2015-10-03 13:14:18 +0100" MODIFIED_BY="[Empty name]" NAME="To 2014" TYPE="JOURNAL_ARTICLE">
<AU>To TH, Agar M, Yates P, Currow DC</AU>
<TI>Prescribing for nausea in palliative care: a cross-sectional national survey of Australian palliative medicine doctors</TI>
<SO>Journal of Palliative Medicine</SO>
<YR>2014</YR>
<VL>17</VL>
<NO>9</NO>
<PG>1032-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Twycross-1998" MODIFIED="2015-06-25 07:59:31 +0100" MODIFIED_BY="[Empty name]" NAME="Twycross 1998" TYPE="JOURNAL_ARTICLE">
<AU>Twycross R, Back I</AU>
<TI>Nausea and vomiting in advanced cancer</TI>
<SO>European Journal of Palliative Care</SO>
<YR>1998</YR>
<VL>5</VL>
<PG>39-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Twycross-2014" MODIFIED="2015-03-06 11:35:51 +0000" MODIFIED_BY="[Empty name]" NAME="Twycross 2014" TYPE="BOOK">
<AU>Twycross R, Wilcock A, Howard P</AU>
<SO>Palliative Care Formulary</SO>
<YR>2014</YR>
<EN>5th</EN>
<PB>palliativedrugs.com</PB>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2015-08-28 14:26:59 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2015-08-28 14:21:17 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2015-08-28 14:18:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fletcher-2014">
<CHAR_METHODS MODIFIED="2015-03-06 14:12:15 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled non-inferiority crossover trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-18 10:06:51 +0000" MODIFIED_BY="[Empty name]">
<P>Adults with active cancer and self-reported nausea at least 4 out of 10 (n=22 enrolled, 20 of whom completed the study). Many participants (unspecified) were attending the bone marrow transplant clinic, some were enrolled from the palliative care clinic or palliative care in-patient setting. For full inclusion and exclusion criteria see Fletcher 2014.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-08-28 14:18:10 +0100" MODIFIED_BY="[Empty name]">
<P>ABH gel (contains lorazepam, diphenhydramine and haloperidol) or placebo gel rubbed on the wrist.</P>
<P>ABH gel contains lorazepam 20mg, diphenhydramine 250mg, haloperidol 20mg, lecithin organogel 2mL, ethoxydiglycol 0.83mL, water 0.2mL, pluronic gel 20% (sufficient to make 10mL). These 10mL were divided into ten doses of 1mL.</P>
<P>Placebo was 1mL pluronic lecithin organogel alone.</P>
<P>If no effect (up to 1 point on 0 to 10 scale) was seen after one hour, the participant was offered other medication for nausea and was considered to have completed the trial.</P>
<P>Otherwise the participant crossed over to the other treatment after four hours.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-03-06 14:12:15 +0000" MODIFIED_BY="[Empty name]">
<P>Primary outcome: difference in nausea score from baseline to 60 minutes after intervention. A change of 2 points on a 0 to 10 scale was thought to be significant.</P>
<P>Secondary outcomes: difference in vomiting episodes and side effects determined by the Memorial Symptom Assessment Scale - Condensed.</P>
<P>Assessments were made at baseline (before administration of gel), 30, 60, 90, 120, 180, 240 minutes.</P>
<P>Participants were also asked questions about the perceived effectiveness of each gel.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-08-28 14:18:18 +0100" MODIFIED_BY="[Empty name]">
<P>There was no significant difference in the change in nausea scores for each group (1.7 +/- 2.05 for the ABH gel group and 0.9 +/- 2.45 for the placebo group on a 0 to10 scale; P = 0.42). Authors concluded that placebo was non-inferior to ABH gel. A previous study had shown that there was no significant absorption of haloperidol via this route (<LINK REF="STD-Smith-2012a" TYPE="STUDY">Smith 2012a</LINK>).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2015-06-17 14:20:48 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2014-08-11 15:16:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Abdelsayed-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-11 15:16:34 +0100" MODIFIED_BY="[Empty name]">
<P>Review article - not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-11 15:15:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bleicher-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-11 15:15:26 +0100" MODIFIED_BY="[Empty name]">
<P>Pilot retrospective study - not a RCT; unclear whether population is palliative; unable to isolate effectiveness of haloperidol as given with other agents</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-03 13:28:07 +0000" MODIFIED_BY="Jessica R Thomas" STUDY_ID="STD-Bregni-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-03 13:28:07 +0000" MODIFIED_BY="Jessica R Thomas">
<P>Not a RCT; prophylaxis not treatment; bone marrow transplantation rather than palliative context</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-11 15:15:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Buttner-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-11 15:15:27 +0100" MODIFIED_BY="[Empty name]">
<P>Review article - not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-11 15:15:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Casey-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-11 15:15:27 +0100" MODIFIED_BY="[Empty name]">
<P>Review article - not a RCT; unclear whether population is palliative</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-03 13:28:14 +0000" MODIFIED_BY="Jessica R Thomas" STUDY_ID="STD-Cerchietti-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-03 13:28:14 +0000" MODIFIED_BY="Jessica R Thomas">
<P>RCT but not of haloperidol</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-11 15:15:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cheung-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-11 15:15:28 +0100" MODIFIED_BY="[Empty name]">
<P>Review article - not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-11 15:15:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chiu-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-11 15:15:28 +0100" MODIFIED_BY="[Empty name]">
<P>Review article - not a RCT; focus on antiemetics other than haloperidol</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-25 15:14:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chow-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-25 15:14:14 +0000" MODIFIED_BY="[Empty name]">
<P>Review article - not a RCT; not a palliative population (acute gastroenteritis); no mention of haloperidol</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-25 15:14:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Christman-1974">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-25 15:14:14 +0000" MODIFIED_BY="[Empty name]">
<P>Not a palliative population</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-11 15:15:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Christo-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-11 15:15:29 +0100" MODIFIED_BY="[Empty name]">
<P>Review article - not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-11 15:15:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Clary-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-11 15:15:30 +0100" MODIFIED_BY="[Empty name]">
<P>Review article - not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-06 09:24:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cole-1974">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-06 09:24:19 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear whether patient group restricted to palliative care patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-10 16:21:16 +0100" MODIFIED_BY="Jessica R Thomas" STUDY_ID="STD-Cole-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-10 16:21:16 +0100" MODIFIED_BY="Jessica R Thomas">
<P>Case report</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-06 12:30:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Davis-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-06 12:30:31 +0100" MODIFIED_BY="[Empty name]">
<P>Systematic review, but no RCTs including haloperidol described</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-06-17 14:20:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-De-Vries-1969">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-06-17 14:20:48 +0100" MODIFIED_BY="[Empty name]">
<P>Not a palliative population (mixed - with diagnosis of "functional gastrointestinal disorders" with "an evident psychosomatic component")</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-11 15:15:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-DiVall-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-11 15:15:30 +0100" MODIFIED_BY="[Empty name]">
<P>Review article - not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-11 15:15:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ettinger-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-11 15:15:31 +0100" MODIFIED_BY="[Empty name]">
<P>Review article - not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-11 15:15:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ettinger-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-11 15:15:31 +0100" MODIFIED_BY="[Empty name]">
<P>Review article - not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-11 15:15:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Feyer-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-11 15:15:31 +0100" MODIFIED_BY="[Empty name]">
<P>Review article - not a RCT; no mention of haloperidol</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-25 15:14:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Findlay-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-25 15:14:14 +0000" MODIFIED_BY="[Empty name]">
<P>Unable to isolate effectiveness of haloperidol as given with other agents; not a palliative care population</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-06 12:31:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fischberg-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-06 12:31:31 +0100" MODIFIED_BY="[Empty name]">
<P>RCT but not of haloperidol (droperidol), and not restricted to palliative care patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-25 15:14:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Getto-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-25 15:14:14 +0000" MODIFIED_BY="[Empty name]">
<P>Review article - not a RCT; not a palliative population</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-11 15:15:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Glare-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-11 15:15:33 +0100" MODIFIED_BY="[Empty name]">
<P>Review article - not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-11 15:15:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Glare-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-11 15:15:33 +0100" MODIFIED_BY="[Empty name]">
<P>Review article - not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-11 15:15:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gonzales-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-11 15:15:33 +0100" MODIFIED_BY="[Empty name]">
<P>Review article - not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-08 17:32:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Grunberg-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-08 17:32:16 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial but not restricted to palliative care patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-11 15:15:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Grunberg-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-11 15:15:34 +0100" MODIFIED_BY="[Empty name]">
<P>Review article - not a RCT; no mention of haloperidol</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-25 15:14:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hardy-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-25 15:14:14 +0000" MODIFIED_BY="[Empty name]">
<P>Prospective, open-label, uncontrolled study - not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-11 15:15:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Herndon-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-11 15:15:35 +0100" MODIFIED_BY="[Empty name]">
<P>Review article - not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-11 15:15:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Herrstedt-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-11 15:15:35 +0100" MODIFIED_BY="[Empty name]">
<P>Review article - not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-11 15:15:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jordan-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-11 15:15:36 +0100" MODIFIED_BY="[Empty name]">
<P>Review article - not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-25 14:21:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kohara-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-25 14:21:29 +0100" MODIFIED_BY="[Empty name]">
<P>Retrospective notes review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-14 17:10:48 +0100" MODIFIED_BY="Jessica R Thomas" STUDY_ID="STD-Ladabaum-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-14 17:10:48 +0100" MODIFIED_BY="Jessica R Thomas">
<P>Review - no mention of haloperidol</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-25 15:14:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liem_x002d_Moolenar-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-25 15:14:14 +0000" MODIFIED_BY="[Empty name]">
<P>Not a palliative population - healthy male volunteers</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-11 15:15:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lohr-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-11 15:15:36 +0100" MODIFIED_BY="[Empty name]">
<P>Review article - not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-11 15:15:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McHugh-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-11 15:15:37 +0100" MODIFIED_BY="[Empty name]">
<P>Review article - not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-11 15:15:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McNicol-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-11 15:15:37 +0100" MODIFIED_BY="[Empty name]">
<P>Review article - not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-10 11:30:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mercadante-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-10 11:30:38 +0100" MODIFIED_BY="[Empty name]">
<P>Systematic review but no mention of haloperidol</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-11 15:15:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Naeim-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-11 15:15:38 +0100" MODIFIED_BY="[Empty name]">
<P>Review article - not a RCT; no mention of haloperidol</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-11 15:15:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Navari-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-11 15:15:38 +0100" MODIFIED_BY="[Empty name]">
<P>Review article - not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-08 17:31:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Neidhart-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-08 17:31:21 +0100" MODIFIED_BY="[Empty name]">
<P>Prophylaxis rather than treatment of emesis; unclear whether population is palliative</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-11 15:15:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-O_x0027_Connor-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-11 15:15:39 +0100" MODIFIED_BY="[Empty name]">
<P>Review article - not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-01-27 13:53:53 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Owens-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-01-27 13:53:53 +0000" MODIFIED_BY="[Empty name]">
<P>Prophylaxis rather than treatment of emesis; unclear whether population is palliative</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-11 15:15:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Perkins-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-11 15:15:39 +0100" MODIFIED_BY="[Empty name]">
<P>Cochrane systematic review - not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-11 15:15:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pleuvry-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-11 15:15:40 +0100" MODIFIED_BY="[Empty name]">
<P>Review article - not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-25 15:14:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Porreca-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-25 15:14:14 +0000" MODIFIED_BY="[Empty name]">
<P>Review article - not a RCT; not a palliative population (patients with chronic pain)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-11 15:15:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ripamonti-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-11 15:15:41 +0100" MODIFIED_BY="[Empty name]">
<P>Review article - not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-14 17:10:53 +0100" MODIFIED_BY="Jessica R Thomas" STUDY_ID="STD-Robbins-1975">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-14 17:10:53 +0100" MODIFIED_BY="Jessica R Thomas">
<P>Population not necessarily palliative; treatment of symptoms of gastritis/gastroenteritis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-11 15:15:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Roeland-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-11 15:15:41 +0100" MODIFIED_BY="[Empty name]">
<P>Review article - not a RCT; stem cell transplant rather than palliative context</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-06 10:39:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Saller-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-06 10:39:39 +0100" MODIFIED_BY="[Empty name]">
<P>Prophylaxis not treatment of chemotherapy-associated nausea and vomiting</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-11 15:15:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Siden-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-11 15:15:42 +0100" MODIFIED_BY="[Empty name]">
<P>Case report - not a RCT; child</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-08 17:31:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Silvey-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-08 17:31:04 +0100" MODIFIED_BY="[Empty name]">
<P>Prophylaxis rather than treatment of emesis; unclear whether population is palliative</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-06-17 14:19:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Smith-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-06-17 14:19:57 +0100" MODIFIED_BY="[Empty name]">
<P>Population not palliative (volunteers)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-06-17 14:20:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Smith-2012a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-06-17 14:20:02 +0100" MODIFIED_BY="[Empty name]">
<P>Population not palliative (volunteers)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-11 15:15:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sperry-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-11 15:15:42 +0100" MODIFIED_BY="[Empty name]">
<P>Review article - not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-25 15:14:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stapleton-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-25 15:14:14 +0000" MODIFIED_BY="[Empty name]">
<P>Review article - not a RCT; not a palliative population (patients with gastroparesis from any cause)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-11 15:15:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tatum-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-11 15:15:43 +0100" MODIFIED_BY="[Empty name]">
<P>Review article - not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-25 15:14:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tornetta-1971">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-25 15:14:14 +0000" MODIFIED_BY="[Empty name]">
<P>Postoperative nausea and vomiting</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-25 15:14:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tornetta-1972">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-25 15:14:14 +0000" MODIFIED_BY="[Empty name]">
<P>Prophylaxis of postoperative nausea and vomiting</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-11 15:15:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Trigg-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-11 15:15:44 +0100" MODIFIED_BY="[Empty name]">
<P>Review article - not a RCT; stem cell transplant rather than palliative context</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-11 15:15:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Trigg-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-11 15:15:44 +0100" MODIFIED_BY="[Empty name]">
<P>Review article - not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-11 15:15:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weschules-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-11 15:15:46 +0100" MODIFIED_BY="[Empty name]">
<P>Not a RCT - retrospective notes review; haloperidol given with other agents</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-11 15:15:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-White-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-11 15:15:48 +0100" MODIFIED_BY="[Empty name]">
<P>Case study - not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>RCT - randomised controlled trial</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2015-03-06 14:12:15 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2015-08-28 14:26:59 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2015-08-28 14:26:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ACTRN12610000481077">
<CHAR_STUDY_NAME MODIFIED="2015-08-28 14:21:27 +0100" MODIFIED_BY="[Empty name]">
<P>The effectiveness of guideline-driven antiemetic therapy versus single agent antiemetic therapy in patients with cancer and nausea not related to cancer therapy.</P>
<P>A two-stage trial of response to antiemetic therapy in patients with cancer and nausea not related to anticancer therapy. Study 1: a randomised open label study of guideline-driven targeted antiemetic therapy versus single agent antiemetic therapy.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2015-08-28 14:21:31 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised Controlled Trial</P>
<P>Multi-centre, open-label randomised parallel arm trial. Participants are randomised to active treatment arms 1 or 2.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-08-28 14:21:32 +0100" MODIFIED_BY="[Empty name]">
<P>Patients with cancer and nausea not related to anticancer therapy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-08-28 14:21:40 +0100" MODIFIED_BY="[Empty name]">
<P>Arm 1: targeted guideline-driven antiemetic therapy dependent on presumed cause of nausea.</P>
<P>Arm 2: haloperidol in a three-step dose escalation schedule from 1mg over 24 hours to 3mg over 24 hours given orally or parenterally (subcutaneously).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-08-28 14:21:41 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: response to treatment at 72 hours. Response defined as at least a two-point improvement in average nausea score from baseline and final score less than 3 on an 11-point numeric rating scale.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2015-08-28 14:21:42 +0100" MODIFIED_BY="[Empty name]">
<P>First enrolment 15 June 2010.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2015-03-11 10:41:23 +0000" MODIFIED_BY="[Empty name]">
<P>Professor Patsy Yates</P>
<P>Head of School, Faculty of Health, School - Nursing</P>
<P>Queensland University of Technology, Brisbane QLD 4001</P>
<P>Australia</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2015-08-28 14:26:59 +0100" MODIFIED_BY="[Empty name]">
<P>Preliminary results of this study were published as a conference abstract in 2014 (see Yates 2010 secondary reference).</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2015-08-28 14:21:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ACTRN12615000177550">
<CHAR_STUDY_NAME MODIFIED="2015-08-28 14:20:52 +0100" MODIFIED_BY="[Empty name]">
<P>A randomised, controlled, double blind study of oral methotrimeprazine versus oral haloperidol in patients with cancer and nausea not related to anticancer therapy (Nausea study 3), to compare the effectiveness of oral methotrimeprazine versus oral haloperidol in improving the management of nausea in patients with cancer and nausea not related to anticancer therapy.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2015-08-28 14:21:19 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-08-28 14:21:20 +0100" MODIFIED_BY="[Empty name]">
<P>Patients with cancer and nausea not related to anticancer therapy, with nausea severity of at least 3 on an 11 point numeric rating scale (0 no nausea to 10 worst possible nausea).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-06 14:28:01 +0000" MODIFIED_BY="[Empty name]">
<P>Blinded encapsulated oral methotrimeprazine (6.25mg) or haloperidol (1.5mg) given once daily for three intervention days. If no response at 24 or 48 hours, the dose of the study drug can be increased to twice daily. Rescue medication of metoclopramide or domperidone will be available.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-03-06 14:32:33 +0000" MODIFIED_BY="[Empty name]">
<P>Primary outcome: response to treatment at 72 hours from first study drug administration. Response defined as more than or equal to a two point improvement from baseline for average nausea over the preceding 24 hours on an 11 point numeric rating scale.</P>
<P>Secondary outcomes: best nausea score over the preceding 24 hours; complete response (defined as at least two-point improvement from baseline and a score of less than 3 for average nausea over preceding 24 hours, on 0 to 10 numeric rating scale; response; number of episodes of vomiting, not including retching; number of rescue antiemetic doses; toxicity. </P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2015-03-06 14:33:03 +0000" MODIFIED_BY="[Empty name]">
<P>First enrolment 02 March 2015</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2015-03-06 14:35:00 +0000" MODIFIED_BY="[Empty name]">
<P>Prof Janet R Hardy, Director of Palliative Care Mater Health Services, Raymond Terrace, South Brisbane QLD 4101 Australia </P>
<P>+617 31632775</P>
<P>janet.hardy@mater.org.au</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2015-03-06 14:33:38 +0000" MODIFIED_BY="[Empty name]">
<P>http://www.anzctr.org.au/ACTRN12615000177550.aspx</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2015-08-28 14:21:17 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2015-03-15 00:37:39 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-15 00:37:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fletcher-2014">
<DESCRIPTION>
<P>"The study biostatistician generated the randomisation list."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2015-03-15 00:37:34 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-15 00:37:34 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fletcher-2014">
<DESCRIPTION>
<P>"Randomisation was done in the investigational drug pharmacy with allocation concealed by the use of sealed opaque envelopes not accessible to investigators."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2015-03-15 00:41:44 +0000" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-03-15 00:41:44 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fletcher-2014">
<DESCRIPTION>
<P>Described as double-blind. Participants received ABH gel or placebo gel in randomised order.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2015-03-15 00:42:34 +0000" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-03-15 00:42:34 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fletcher-2014">
<DESCRIPTION>
<P>Participants and investigators not aware of which treatment was being used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2015-03-15 00:47:33 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-03-15 00:47:33 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fletcher-2014">
<DESCRIPTION>
<P>Two of the 22 participants did not complete both arms of the study, because they "did not feel like waiting the length of the study but denied side effects from the medications". It is not clear which treatments were completed for the two who did not complete the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2015-03-15 00:46:40 +0000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-15 00:46:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fletcher-2014">
<DESCRIPTION>
<P>Placebo is reported to be non-inferior to ABH gel in this study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2015-08-28 14:21:17 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-28 14:21:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fletcher-2014">
<DESCRIPTION>
<P>This is a relatively small study. Participants were enrolled from the bone marrow transplant clinic, inpatient palliative care unit or seen as an inpatient by the palliative care team. The study authors state that, "Many patients were bone marrow transplant patients" but it is not clear what proportion. The study participants may not be fully representative of patients receiving palliative care in other settings. However, this is unlikely to have been a significant cause of bias for the study findings.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES"/>
<FIGURES MODIFIED="2015-10-13 12:39:56 +0100" MODIFIED_BY="Anna Hobson">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2015-10-13 12:39:56 +0100" MODIFIED_BY="Anna Hobson" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAoIAAAUGCAYAAAAFdtBVAACAAElEQVR42uy9D2SX3////yFJksTM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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2015-08-28 14:21:18 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEACAMAAABVk4iuAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2015-08-28 14:21:18 +0100" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAATYAAAFzCAIAAAA7S7IhAAAPkUlEQVR42u3dvY6dRRLG8ZGQEIED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==
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2015-08-28 14:29:01 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2015-08-28 14:27:04 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2015-07-30 13:16:46 +0100" MODIFIED_BY="Anna Hobson">Search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2015-08-28 14:27:04 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>CENTRAL</B>
</P>
<P>#1 MeSH descriptor: [Vomiting] explode all trees</P>
<P>#2 MeSH descriptor: [Nausea] explode all trees</P>
<P>#3 vomit*:ti,ab,kw (Word variations have been searched)</P>
<P>#4 nause*:ti,ab,kw (Word variations have been searched)</P>
<P>#5 (emesis or emet*):ti,ab,kw (Word variations have been searched)</P>
<P>#6 (antiemet* or anti-emet*):ti,ab,kw (Word variations have been searched)</P>
<P>#7 #1 or #2 or #3 or #4 or #5 or #6</P>
<P>#8 MeSH descriptor: [Haloperidol] this term only</P>
<P>#9 (haloperidol or enabran* or halopidol* or halozen* or limerix* or neupram* or zetoridal* or haldol* or serenace* or haloper* or loperidol* or "uni haloper*" or novo-peridol* or peridol* or alternus* or serenase* or buteridol* or duraperidol* or elaubat* or haloneural* or sigaperidol* or aloperidin* or sevium$.mp. or cizoren* or pericate* or peridor* or bioperidol* or kepsidol* or pulsit* or serenelfi*):ti,ab,kw (Word variations have been searched)</P>
<P>#10 (senorm* or cereen* or h-tab* or halo-p or halomed* or halopol* or haricon* or haridol* or perida* or polyhadon* or schizopol* or tensidol* or dozic* or fortunan* or halperon*):ti,ab,kw (Word variations have been searched)</P>
<P>#11 butyrophenone*:ti,ab,kw (Word variations have been searched)</P>
<P>#12 MeSH descriptor: [Butyrophenones] explode all trees</P>
<P>#13 #8 or #9 or #10 or #11 or #12</P>
<P>
<B>MEDLINE</B>
</P>
<P>1. RANDOMIZED CONTROLLED TRIAL.pt.<BR/>2. CONTROLLED CLINICAL TRIAL.pt.<BR/>3. RANDOMIZED CONTROLLED TRIALS.sh.<BR/>4. RANDOM ALLOCATION.sh.<BR/>5. DOUBLE BLIND METHOD.sh.<BR/>6. SINGLE BLIND METHOD.sh.<BR/>7. 1 or 2 or 3 or 4 or 5 or 6<BR/>8. (ANIMALS not HUMAN).sh.<BR/>9. 7 not 8<BR/>10. CLINICAL TRIAL.pt.<BR/>11. exp CLINICAL TRIALS/<BR/>12. (clin$ adj25 trial$).ti,ab.<BR/>13. ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).ti,ab.<BR/>14. PLACEBOS.sh.<BR/>15. placebo$.ti,ab.<BR/>16. random$.ti,ab.<BR/>17. RESEARCH DESIGN.sh.<BR/>18. 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17<BR/>19. 18 not 8<BR/>20. 19 not 9<BR/>21. COMPARATIVE STUDY.sh.<BR/>22. exp EVALUATION STUDIES/<BR/>23. FOLLOW UP STUDIES.sh.<BR/>24. PROSPECTIVE STUDIES.sh.<BR/>25. (control$ or prospectiv$ or volunteer$).ti,ab.<BR/>26. 21 or 22 or 23 or 24 or 25<BR/>27. 26 not 8<BR/>28. 27 not (9 or 20)<BR/>29. 9 or 20 or 28<BR/>30. nause$.mp.<BR/>31. vomit$.mp.<BR/>32. emesis.mp.<BR/>33. emet$.mp.<BR/>34. anti-eme$.mp.<BR/>35. antieme$.mp.<BR/>36. antiemetics.sh.<BR/>37. nausea.sh.<BR/>38. vomiting.sh.<BR/>39. 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38<BR/>40. haloperidol.mp.<BR/>41. enabran$.mp.<BR/>42. halopidol$.mp.<BR/>43. halozen$.mp.<BR/>44. limerix$.mp.<BR/>45. neupram$.mp.<BR/>46. zetoridal$.mp.<BR/>47. haldol$.mp.<BR/>48. serenace$.mp.<BR/>49. haloper$.mp.<BR/>50. loperidol$.mp.<BR/>51. "uni haloper$".mp.<BR/>52. novo-peridol$.mp.<BR/>53. peridol$.mp.<BR/>54. alternus$.mp.<BR/>55. serenase$.mp.<BR/>56. buteridol$.mp.<BR/>57. duraperidol$.mp.<BR/>58. elaubat$.mp.<BR/>59. haloneural$.mp.<BR/>60. sigaperidol$.mp.<BR/>61. aloperidin$.mp.<BR/>62. sevium$.mp.<BR/>63. cizoren$.mp.<BR/>64. pericate$.mp.<BR/>65. peridor$.mp.<BR/>66. bioperidol$.mp.<BR/>67. avant$.mp.<BR/>68. kepsidol$.mp.<BR/>69. pulsit$.mp.<BR/>70. serenelfi$.mp.<BR/>71. senorm$.mp.<BR/>72. cereen$.mp.<BR/>73. h-tab$.mp.<BR/>74. halo-p.mp.<BR/>75. halomed$.mp.<BR/>76. halopol$.mp.<BR/>77. haricon$.mp.<BR/>78. haridol$.mp.<BR/>79. perida$.mp.<BR/>80. polyhadon$.mp.<BR/>81. schizopol$.mp.<BR/>82. tensidol$.mp.<BR/>83. dozic$.mp.<BR/>84. fortunan$.mp.<BR/>85. halperon$.mp.<BR/>86. 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 69 or 70 or 71 or 72 or 73 or 74 or 75 or 76 or 77 or 78 or 79 or 80 or 81 or 82 or 83 or 84 or 85<BR/>87. butyrophenone$.mp.<BR/>88. exp butyrophenones/<BR/>89. 87 or 88<BR/>90. 86 or 89<BR/>91. 29 and 39 and 90</P>
<P>
<B>EMBASE</B>
</P>
<P>1 exp Vomiting/ (131250)<BR/>2 exp Nausea/ (152267)<BR/>3 vomit*.tw. (73323)<BR/>4 nause*.tw. (66297)<BR/>5 (emesis or emet*).tw. (12303)<BR/>6 (antiemet* or anti-emet*).tw. (9283)<BR/>7 or/1-6 (248098)<BR/>8 exp Butyrophenones/ (66670)<BR/>9 butyrophenone*.tw. (961)<BR/>10 (senorm* or cereen* or h-tab* or halo-p or halomed* or halopol* or haricon* or haridol* or perida* or polyhadon* or schizopol* or tensidol* or dozic* or fortunan* or halperon*).tw. (178)<BR/>11 (haloperidol or enabran* or halopidol* or halozen* or limerix* or neupram* or zetoridal* or haldol* or serenace* or haloper* or loperidol* or "uni haloper*" or novo-peridol* or peridol* or alternus* or serenase* or buteridol* or duraperidol* or elaubat* or haloneural* or sigaperidol* or aloperidin* or sevium* or cizoren* or pericate* or peridor* or bioperidol* or kepsidol* or pulsit* or serenelfi*).tw. (22865)<BR/>12 or/8-11 (68762)<BR/>13 random$.tw. (927492)<BR/>14 factorial$.tw. (24183)<BR/>15 crossover$.tw. (50980)<BR/>16 cross over$.tw. (22914)<BR/>17 cross-over$.tw. (22914)<BR/>18 placebo$.tw. (209888)<BR/>19 (doubl$ adj blind$).tw. (151391)<BR/>20 (singl$ adj blind$).tw. (15179)<BR/>21 assign$.tw. (249822)<BR/>22 allocat$.tw. (88369)<BR/>23 volunteer$.tw. (186012)<BR/>24 Crossover Procedure/ (40652)<BR/>25 double-blind procedure.tw. (222)<BR/>26 Randomized Controlled Trial/ (355913)<BR/>27 Single Blind Procedure/ (19061)<BR/>28 or/13-27 (1477437)<BR/>29 (animal/ or nonhuman/) not human/ (4687675)<BR/>30 28 not 29 (1306909)<BR/>31 7 and 12 and 30 (1217)<BR/>32 (201311* or 201312* or 2014*).dd. (1574688)<BR/>33 31 and 32 (34)</P>
<P>
<B>CINAHL</B>
</P>
<P>S13 S7 AND S12</P>
<P>S12 S8 OR S9 OR S10 OR S11</P>
<P>S11 (haloperidol or enabran* or halopidol* or halozen* or limerix* or neupram* or zetoridal* or haldol* or serenace* or haloper* or loperidol* or "uni haloper*" or novo-peridol* or peridol* or alternus* or serenase* or buteridol* or duraperidol* or elaubat* or haloneural* or sigaperidol* or aloperidin* or sevium* or cizoren* or pericate* or peridor* or bioperidol* or kepsidol* or pulsit* or serenelfi*)</P>
<P>S10 (senorm* or cereen* or h-tab* or halo-p or halomed* OR halopol* OR haricon* or haridol* or perida* or polyhadon* or schizopol* or tensidol* or dozic* or fortunan* or halperon*)</P>
<P>S9 butyrophenone*</P>
<P>S8 (MH "Antipsychotic Agents, Butyrophenone+")</P>
<P>S7 S1 OR S2 OR S3 OR S4 OR S5 OR S6</P>
<P>S6 (antiemet* or anti-emet*)</P>
<P>S5 (emesis or emet*)</P>
<P>S4 nause*</P>
<P>S3 vomit*</P>
<P>S2 (MH "Nausea")</P>
<P>S1 (MH "Vomiting+")</P>
<P>
<B>AMED</B>
</P>
<P>1. exp Vomiting/</P>
<P>2. exp Nausea/</P>
<P>3. vomit*.tw.</P>
<P>4. nause*.tw.</P>
<P>5. (emesis or emet*).tw.</P>
<P>6. (antiemet* or anti-emet*).tw.</P>
<P>7. or/1-6</P>
<P>8. butyrophenone*.tw.</P>
<P>9. (senorm* or cereen* or h-tab* or halo-p or halomed* or halopol* or haricon* or haridol* or perida* or polyhadon* or schizopol* or tensidol* or dozic* or fortunan* or halperon*).tw.</P>
<P>10. (haloperidol or enabran* or halopidol* or halozen* or limerix* or neupram* or zetoridal* or haldol* or serenace* or haloper* or loperidol* or "uni haloper*" or novo-peridol* or peridol* or alternus* or serenase* or buteridol* or duraperidol* or elaubat* or haloneural* or sigaperidol* or aloperidin* or sevium* or cizoren* or pericate* or peridor* or bioperidol* or kepsidol* or pulsit* or serenelfi*).tw.</P>
<P>11. or/8-10</P>
<P>12. 7 and 11</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;1 study included in quantitative synthesis (meta-analysis not undertaken as only one RCT completed and fully published)&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;1 study included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;0 studies included in previous version of review &lt;/p&gt;&lt;p&gt;&lt;/p&gt;"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;1 NEW completed study included (2014)&lt;/p&gt;&lt;p&gt;&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;38 full-text articles assessed for eligibility (2013)&lt;/p&gt;&lt;p&gt;2 articles assessed (2014)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;417 records screened (2013)&lt;/p&gt;&lt;p&gt;60 records screened (2014)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;417 records after duplicates removed (2013)&lt;/p&gt;&lt;p&gt;60 records (2014)&lt;/p&gt;&lt;p&gt;&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;503 records identified through database searching (2007 to 2013)&lt;/p&gt;&lt;p&gt;60 records identified (2014)&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;0 additional records identified through other sources &lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;379 records excluded (2013)&lt;/p&gt;&lt;p&gt;58 records excluded (2014)&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;38 full-text articles excluded, with reasons (2013):&lt;/p&gt;&lt;p&gt;34 not RCTs&lt;/p&gt;&lt;p&gt;3 included adults not suffering from incurable progressive medical condition&lt;/p&gt;&lt;p&gt;1 did not involve the use of haloperidol.&lt;/p&gt;&lt;p&gt;1 conference abstract excluded (2014): not full publication; ongoing trial.&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>